Journal articles on the topic 'Coates and Company'
To see the other types of publications on this topic, follow the link: Coates and Company.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Coates and Company.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Englund, Magnus. "Isokon Furniture — Modernist Dreams in Plywood." Louis I. Kahn – The Permanence, no. 58 (2018): 82–85. http://dx.doi.org/10.52200/58.a.ky5uaj0p.
Full textAbstract:
The Isokon Furniture Company was never commercially successful, yet its legacy has stubbornly refused to die and disappear. Even today, this radical collection of plywood furniture is manufactured and used. The main reason is of course the names associated with it: Jack Pritchard, Wells Coates, Marcel Breuer, Walter Gropius, László Moholy-Nagy and – more recently – Edward Barber & Jay Osgerby. The genius little Isokon Penguin Donkey, first designed by the Austrian émigré architect Egon Riss in 1939 and marketed by publisher Allen Lane’s then new imprint Penguin Books, is particularly popular with younger generations of design students.
2
Coates, L. C., A. Kronbergs, A. T. Sprabery, S. Y. Park, B. Combe, and A. Deodhar. "SAT0410 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1157–58. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3994.
Full textAbstract:
Background:Biologic disease-modifying antirheumatic drugs such as ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, are commonly prescribed to patients with psoriatic arthritis (PsA) in combination with conventional synthetic disease-modifying antirheumatic drugs (cDMARDs). Previous studies have shown that, after 24 weeks of treatment, IXE is efficacious with or without concomitant cDMARD therapy in patients with active PsA.1,2However, there is limited evidence demonstrating efficacy and safety after 3 years of treatment.Objectives:To evaluate the long-term (3-year) efficacy and safety of IXE in patients with active PsA from SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295) based on concomitant cDMARD use.Methods:Patients were subdivided into the following subgroups: 1) no cDMARD use for 3 years (ixekizumab monotherapy); 2) methotrexate (MTX) use without interruption (i.e., ≤14-day gap of not using MTX), but allowing a change of MTX dose; and 3) any cDMARD (MTX, sulfasalazine, leflunomide, ciclosporin, hydroxychloroquine) use during 3 years without interruption (i.e., ≤14-day gap of not using cDMARDs), but allowing a switch of cDMARD type and/or change of dose. The post-hoc integrated analysis assessed efficacy and safety up to 3 years by three subgroups. Efficacy outcomes included the American College of Rheumatology (ACR) 20/50/70, Psoriasis Area and Severity Index (PASI) 75/90/100, Health Assessment Questionnaire-Disability Index (HAQ-DI) ≥0.35-point improvement. Missing data were imputed using modified non-responder imputation. The IXE 80 mg every 4 weeks (IXEQ4W) dose data are reported here.Results:Overall, IXE-treated patients showed improvement in all efficacy outcomes over 156 weeks, regardless of concomitant cDMARD use. ACR response rates by concomitant cDMARD use at 156 weeks are highlighted in Figure 1. Patients treated with IXEQ4W in the no cDMARD use, MTX, and any cDMARD use subgroups had similar ACR20 (59.1%, 67.0%, and 66.1%, respectively), ACR50 (46.2%, 47.4%, and 46.8%, respectively), and ACR70 (30.7%, 28.4%, and 28.1%, respectively) response rates at 156 weeks. Patients treated with IXEQ4W in the three subgroups also had similar PASI75 (65.5%, 60.8%, and 59.8%, respectively), PASI90 (53.6%, 49.7%, and 48.0%, respectively), and PASI100 (42.2%, 46.2%, and 42.4%, respectively) response rates at 156 weeks. The proportion of patients achieving HAQ-DI improvement ≥0.35 in the three subgroups (51.9%, 45.0%, and 47.5%, respectively) was comparable. The safety profile of IXEQ4W was consistent with that previously reported.1,2A similar proportion of IXEQ4W-treated patients in the three subgroups reported ≥1 treatment-emergent adverse events (TEAEs) regardless of the addition of MTX or other cDMARDs (91.0%, 84.1%, and 83.2%, respectively), and the majority of TEAEs were mild or moderate in all three subgroups.Conclusion:IXEQ4W provided sustained improvements in the signs and symptoms of active PsA. While there are some numerical differences in ACR20/50/70 as well as PASI75/90/100, the overall responses with or without the addition of MTX or other cDMARDs were similar. In this post-hoc analysis, it appears that, for sustained responses over time, IXEQ4W does not require the addition of MTX or other cDMARDs. Addition of MTX or other cDMARDs to IXEQ4W did not negatively impact its favorable long-term safety profile.References:[1]Coates LC, Kishimoto M, Gottlieb A, et al. RMD Open 2017.[2]Nash P, Behrens F, Orbai A-M, et al. RMD Open 2018.Disclosure of Interests:Laura C Coates: None declared, Andris Kronbergs Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, So Young Park Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Bernard Combe Grant/research support from: Novartis, Pfizer, Roche-Chugai, Consultant of: AbbVie; Gilead Sciences, Inc.; Janssen; Eli Lilly and Company; Pfizer; Roche-Chugai; Sanofi, Speakers bureau: Bristol-Myers Squibb; Gilead Sciences, Inc.; Eli Lilly and Company; Merck Sharp & Dohme; Pfizer; Roche-Chugai; UCB, Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB
3
Smolen, J. S., A. Sebba, E. Ruderman, A. Gellett, C. Sapin, A. T. Sprabery, S. Liu Leage, S. Pillai, P. Reis, and P. Nash. "OP0228 EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB (SPIRIT-H2H) WITH AND WITHOUT CONCOMITANT CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 143–44. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4615.
Full textAbstract:
Background:Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 100) (primary endpoint) in patients (pts) with active PsA from SPIRIT-H2H1. SPIRIT-H2H had two major secondary endpoints and achieved both: noninferiority of IXE to ADA for ACR50 at Wk 24, and superiority of IXE to ADA for PASI 100 at Wk 24.Objectives:To determine how concomitant conventional synthetic DMARD (csDMARD) use affects safety and efficacy of IXE and ADA in prespecified subgroups defined by biologic monotherapy, concomitant MTX use, and concomitant csDMARD use through Wk 52 in SPIRIT-H2H.Methods:SPIRIT-H2H (NCT03151551) was a 52-week, multicentre, randomised, open-label, assessor-blinded, parallel-group study evaluating the efficacy and safety of IXE versus ADA in adults with PsA and naïve to biologic DMARDs. Patients were required to have active PsA fulfilling Classification for Psoriatic Arthritis (CASPAR) criteria and ≥3/68 tender and ≥3/66 swollen joints, ≥3% plaque psoriasis BSA involvement, no prior treatment with bDMARDs, and with prior inadequate response to ≥1 csDMARD (but not necessarily current treatment with csDMARDs). Randomization (1:1) was stratified by concomitant use of csDMARD and the presence/absence of moderate to severe PsO (baseline: BSA≥10% + PASI≥12, + static Physician’s Global Assessment≥3). Patients (N=566) received IXE/ADA through 52 wks according to the labelled dose dependent on presence/absence of moderate-to-severe PsO. In this prespecified subgroup analysis by presence or absence of csDMARDs, efficacy outcomes through wk 52 were compared between IXE and ADA using logistic regression models and Fisher’s exact tests. Missing data were imputed using non-responder imputation.Results:At baseline, 167 of 283 IXE-treated patients and 169 of 283 ADA-treated patients had concomitant MTX use. Of these, 9.0% (15/167) and 7.1% (12/169) treated with IXE and ADA, respectively, were taking an additional csDMARD (sulfasalazine, cyclosporine, or leflunomide). A significantly greater proportion of patients on IXE versus ADA achieved the primary endpoint or PASI 100 when used as monotherapy or in combination with csDMARD (Figure 1A and 1C). At Wk 52, the proportion of patients achieving ACR50 was not statistically different between IXE and ADA, regardless of monotherapy or concomitant csDMARD use (Figure 1B). A significantly higher proportion of patients achieved MDA on IXE compared to ADA in the monotherapy subgroup (49% vs 33%), while the response rates were similar in both combination subgroups (Figure 1D). These data support consistent ACR50, PASI 100, and MDA response for IXE across all three subgroups. Frequencies of adverse events were similar across the three subgroups for IXE and ADA (Figure 2).Conclusion:As with prior studies,2,3consistent efficacy across multiple PsA disease-specific endpoints was observed with IXE in SPIRIT-H2H, regardless of whether IXE was taken as monotherapy or in combination with MTX or another csDMARD. No unexpected safety signals were found for either agent.References:[1]Mease et al, Ann Rheum Dis 2020;79:123-31.[2]Coates et al, RMD Open 2017;3:e000567.[3]Nash et al, RMD Open 2018;4:e000692.Disclosure of Interests:Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Anthony Sebba Consultant of: Genentech, Gilead, Lilly, Regeneron Pharmaceuticals Inc., Sanofi, Speakers bureau: Lilly, Roche, Sanofi, Eric Ruderman Consultant of: Pfizer, Amanda Gellett Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Christophe Sapin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Soyi Liu Leage Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Sreekumar Pillai Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Paulo Reis Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB
4
Coates, L. C., D. Sandoval, R. Bolce, C. Y. Lin, K. Stenger, A. T. Sprabery, and A. Kavanaugh. "AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1301–2. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1514.
Full textAbstract:
Background:Ixekizumab (IXE), a high-affinity monoclonal antibody targeting IL-17A, has demonstrated superiority in achieving the combined endpoint of ACR50 and PASI100 at week (Wk) 24 compared to adalimumab (ADA) in the SPIRIT-H2H trial [1]. In this analysis, we looked at the efficacy responses at the individual patient (pt) level to assess consistency over time and at each visit.Objectives:To determine the American College of Rheumatology 50% (ACR50) response and Disease Activity in psoriatic arthritis (PsA) (DAPSA) response in pts treated with IXE and describe response consistency over time and at each visit from Wk 24 through Wk 52.Methods:This post-hoc analysis used data from SPIRIT-H2H (NCT03151551), a phase3b/4 randomised, open-label parallel-group study between IXE and ADA. Pts were randomised to receive either IXE 80 mg, every 4 Wks (IXE Q4W)) or ADA 40 mg, every 2 Wks (ADA Q2W)). The proportion (%) of pts in the intent-to-treat population who achieved each endpoint, either ACR50 or DAPSA≤14, at Wk 24 and at each post-baseline visit out to Wk 52 was assessed. Nine pts with active psoriasis and body surface area (BSA) ≥3% were assessed as PASI=0 at baseline, a medical inconsistency that was resolved using medical judgement. These pts were considered PASI100 responders if PASI=0 and BSA=0 at post baseline visits.Results:A total of 566 patients enrolled in the trial received either IXE (N=283) or ADA (N=283). Of the 143 pts treated with IXE who achieved ACR50 at Wk 24, 65% (N=93) maintained ACR50 at every visit. In total, 83% (N=118) of the ACR50 achievers at Wk 24 maintained ACR50 with some (18% (N=25)) fluctuations, between ACR50 and ACR20 (Figure 1). Of the 132 pts treated with ADA who achieved ACR50 at Wk 24, 55% (N=72) maintained ACR50 at every visit. In total, 80% (N=105) of ACR50 achievers maintained ACR50 with some (25% (N=33)) fluctuations between ACR50 and ACR20 (Table 1). Furthermore, of the174 pts treated with IXE who achieved low DA (DAPSA≤14) at Wk 24, 68% (N=119) maintained low DA at every visit. Of the low DA achievers at Wk 24, 82% (N=142) of pts maintained low DA with some (13% (N=23)) fluctuations between moderate and low DA (Figure 1B). Of the 171 pts treated with ADA who achieved low DA at Wk 24; 57% (N=97) maintained low DA at every visit. In total, 77% (N=131) of low DA achievers at Wk 24 maintained low DA with some (20% (N=34)) fluctuations between moderate and low DA (Table 1).Conclusion:This analysis demonstrates that a numerically higher proportion of pts treated with IXE versus ADA show consistency of response, as measured by ACR50 and DAPSA responses, over time and for each visit at the pt level.References:[1]Mease et al. Ann Rheum Dis. 2020;79(1):123-131Table 1.Consistency over time of the effect of ADA in pts with PsA.IXE Q4W(N=283)ADA Q2W(N=283)ACR50Response,% (n)DAPSA≤14low DA,% (n)ACR50Response,% (n)DAPSA≤14low DA,% (n)Patients who achieved the response at Wk 2451% (143)61% (174)47% (132)60% (171)Achieved endpoint at Wk 24 and maintained out to Wk 52 with some fluctuations*83% (N=118)82% (N=142)80% (105)77% (131)Maintained endpoint at every visit65% (N=93)68% (N=119)55% (72)57% (97)Had some fluctuations*18% (N=25)13% (N=23)25% (33)20% (34)* fluctuations between ACR50 and ACR20, or between low and moderate disease activity.Figure 1.Heatmap diagram describing consistency over time of the effect of IXE in pts with PsA who achieved DAPSA≤14 (low disease activity) at Wk 24.Acknowledgements :Edel Hughes, an employee of Eli Lilly and Company, provided editorial and writing support.Disclosure of Interests:Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB., Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, and Novartis, David Sandoval Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Rebecca Bolce Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Chen-Yen Lin Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Keri Stenger Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company; Johnson and Johnson, Employee of: Eli Lilly and Company, Arthur Kavanaugh Consultant of: AbbVie, Amgen, Eli Lilly, BMS, Pfizer, Novartis, Janssen.
5
Coates, L. C., M. Nissen, C. El Baou, J. Zochling, A. Marchesoni, S. Liu Leage, E. Soriano, V. F. Azevedo, K. Machold, and C. Sapin. "FRI0332 EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM THE SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÏVE TO BDMARDS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 758.1–758. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2830.
Full textAbstract:
Background:Psoriatic arthritis (PsA) is a chronic systemic disease with manifestations affecting musculoskeletal and extra-articular domains. Treatment and assessment of response are therefore major challenges in routine clinical practice. Minimal disease activity (MDA) is a multidimensional endpoint that can define a treatment target1. In SPIRIT-H2H2, a head-to-head clinical trial comparing the efficacy and safety of ixekizumab (IXE) versus) to adalimumab (ADA), the percentage of patients simultaneously achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100), was the primary endpoint in order to reflect improvement in two domains of PsA.Objectives:To evaluate how individual components of the simultaneous achievement of ACR50 and PASI100 compare with those of MDA at week 24.Methods:Patients with active PsA (defined as those with a tender joint count [TJC] ≥ 3/68, a swollen joint count [SJC] ≥ 3/66 and a body surface area [BSA] of active plaque psoriasis ≥ 3%) were randomised 1:1 to approved dosing (according to baseline psoriasis involvement) of IXE or ADA in SPIRIT-H2H, an open label, assessor-blinded study.The proportion of patients meeting each criterion of the composite endpoints was calculated for the intent-to-treat ([ITT], N=566) population and the population of MDA responders at Week 24 (N=235). Missing individual responses were imputed with non-responder status. Spidergrams were generated using SAS 9.4.Results:For both the overall ITT population and the MDA responders population, the use of PASI≤1 or BSA≤3% in the skin-related component of the MDA contributed to the higher response rate relative to the PASI100 response. Thus, the PASI100 response is a more stringent endpoint. Proportions of responders are similar across MDA and ACR50+PASI100 individual components for HAQ and SJC. The high baseline TJC levels (mean TJC: IXE=19.1, ADA=21.3) as opposed to lower levels observed for baseline SJC (mean SJC: IXE=10.1, ADA=10.7) made MDA-TJC criterion (≤1) more difficult to achieve than the equivalent criterion of the ACR50+PASI100 endpoint.Conclusion:Despite the differences in criteria definitions, there are consistent response patterns in the individual components of the simultaneous ACR50+PASI100 and MDA endpoints in particular for the peripheral arthritis domain.References:[1]Smolen, Josef S et al. “Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.”Annals of the rheumatic diseasesvol. 77,1 (2018): 3-17.[2]Mease PJ The SPIRIT H2H study group, et al. “A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.”Annals of the Rheumatic Diseases2020;79:123-131.Disclosure of Interests:Laura C Coates: None declared, Michael Nissen Grant/research support from: Abbvie, Consultant of: Novartis, Lilly, Abbvie, Celgene and Pfizer, Speakers bureau: Novartis, Lilly, Abbvie, Celgene and Pfizer, Celine El Baou Consultant of: Eli Lilly and Company, Jane Zochling Employee of: Jannssen Cilag, Speakers bureau: Janssen Cilag, AbbVie, Novartis, UCB, BMS, Eli Lilly, Antonio Marchesoni Speakers bureau: Abbvie, Pfizer, UCB, Novartis, Celgene, Eli Lilly, Soyi Liu Leage Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Enrique Soriano Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Consultant of: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Speakers bureau: AbbVie, Amber, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer Inc, Roche, Valderilio F Azevedo Grant/research support from: Abbvie, Janssen, Bristol-Myers Squibb, Boehringer-Ingelheim, Lilly and Novartis, Consultant of: Lilly, Novartis, Janssen, Boehringer-Ingelheim, Amgen, Pfizer and Abbvie, Speakers bureau: Sandoz, Celltrion, Lilly, Novartis, Janssen, Boehringer-Ingelheim, Amgen, Pfizer and Abbvie, Klaus Machold Grant/research support from: AbbVie, MSD, UCB, Consultant of: Arsanis, Astro, Baxter, BMS, Celgene, Eli-Lilly, MSD, Pfizer, Roche, Novartis, Sandoz, Speakers bureau: MSD, Pfizer, BMS, Janssen-Cilag, Sandoz, Novartis, Eli-Lilly, Christophe Sapin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company
6
Van Hal, T., M. Mulder, M. Wenink, M. Pasch, J. Van den Reek, and E. De Jong. "AB0842 DISCOVERY OF ARTHRITIS IN PSORIASIS FOR EARLY RHEUMATOLOGIC REFERRAL (DAPPER): A CROSS-SECTIONAL STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1727.1–1727. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4745.
Full textAbstract:
Background:One in three patients with psoriasis (Pso) will develop psoriatic arthritis (PsA) (1). When untreated, this can lead to disability and irreversible joint damage (2). Current screening methods are mostly based on questionnaires. These lack specificity and sensitivity (3,4). Thus, a significant portion of PsA patients remains undetected.Objectives:Our main objective is to ascertain the prevalence of PsA in a cohort of Pso patient, treated at a dermatology outpatient clinic. Secondary, we wish to make a referral tool for dermatologist to detect patients suspected of PsA.Methods:A sample of 300 patients, stratified for current skin therapy (topical, systemic non-biologic, biologic), will be screened by a rheumatology resident for PsA signs and symptoms. When PsA is suspected, patients are referred to a rheumatologist for confirmation. We gather information about demography, treatment (past and current) and comorbidity. On top of that, we gather data on disease specifics (age of onset, disease duration, severity). We store biomaterials and DNA. Eventually, all these data will be used to form a more specific prediction model which can be used at the dermatology department for more efficient referral.Results:We will present preliminary data of the first 100 patients. In this cohort, we found 14 patients with known PsA. 10 patients were suspected of (previously undiagnosed) PsA, and were referred to a rheumatology clinic. Three cases were confirmed, and 4 are still under analysis. This makes the prevalence of PsA in Pso 17-21%. Of these three new cases, one was treated with topical therapy only, one was treated with a biologic, and one received targeted therapy. In the patients with PsA, we found a higher amount of men. On top of that, we found a trend towards more intensive therapy. This may be due to indication bias, were the presence of arthritis may lead to a more aggressive treatment. Interestingly, 2 of the 3 previously undiagnosed PsA patients were treated with a biological for their skin symptoms.Conclusion:Preliminary data of the DAPPER study reveal that the prevalence of confirmed PsA in Pso patients is 17%. If all suspected PsA are confirmed, this rises to 21%. Even under systemic biologic treatment, arthritis can still be active.References:[1]Mease PJ, Gladman DD, Papp KA et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69(5):729-735.[2]Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42(12):1460-1468.[3]Coates LC, Aslam T, Al BF et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 2013;168(4):802-807.[4]Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72(5):736-740.Disclosure of Interests:Tamara van Hal Speakers bureau: Lilly Eli, Michelle Mulder: None declared, Mark Wenink: None declared, Marcel Pasch: None declared, Juul Van den Reek Speakers bureau: Abbvie, Eli Lilly, Elke De Jong Grant/research support from: Abbvie, Janssen Pharmaceutica, Consultant of: AbbVie, Janssen Pharmaceutica, Novartis, Eli Lily and Company, Celgene, and Leo Pharma., Speakers bureau: AbbVie, Janssen Pharmaceutica, Novartis, Eli Lily and Company, Celgene, and Leo Pharma.
7
Poddubnyy, D., P. J. Mease, F. Van den Bosch, J. Braun, A. Gottlieb, L. C. Coates, V. Chandran, et al. "AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1715.1–1716. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2719.
Full textAbstract:
Background:Inflammatory involvement of the axial skeleton (sacroiliac joints and / or spine) is one of the relatively frequent musculoskeletal manifestations associated with psoriasis / psoriatic arthritis (PsA). There is an urgent need for an evidence-based definition for axial involvement in PsA that would identify a subgroup of patients within the heterogeneous PsA population to conduct observational, interventional and translational studies. ASAS and GRAPPA embarked on a collaborative initiative to develop a definition of axial involvement in PsA.Objectives:To perform a survey to identify variables relevant in the identification of the presence of axial involvement in PsA among members of ASAS and GRAPPA.Methods:The online survey utilized thePAPRIKAmethodology (PotentiallyAllPairwiseRanKings of all possibleAlternatives) that determines decision-makers’ part-worth utilities representing the relative importance of the attributes. Participants were exposed to number of clinical scenarios and were prompted to decide which of the scenarios is more compatible with axial involvement in PsA unless they are equal (Figure). The constant stem of each scenario was “a patient diagnosed with psoriatic arthritis fulfilling the CASPAR criteria”; the variable part included 13 common spondyloarthritis variables (Table). Variables were ranked according to their relative importance.Results:The survey was completed by 186 ASAS/GRAPPA members (63 ASAS only, 80 GRAPPA only, and 43 both societies). The ranking of the variables is presented inTable. The highest ranked parameters indicative of axial involvement in a patient with PsA were presence of typical radiographic or MRI changes in the sacroiliac joints and/or spine followed by the presence of chronic back pain and then inflammatory back pain. A separate analysis of ASAS and GRAPPA members provided the similar results concerning the relevance of the variables.Conclusion:Objective signs of inflammatory involvement of the axial skeleton are the most important indicators of axial disease in PsA in the opinion of the experts. A prospective cohort study is currently being planned to address the value of these and other variables in defining axial involvement in PsA.Table.Ranking of the parameters relevant to deciding on the presence of axial involvement in a PsA patient in the opinion of ASAS and GRAPPA members (n=186).NParametersMedian rankMean rank1Presence of structural damage on an X-ray of SIJ22.82Presence of structural damage on an X-ray of spine3.54.13Presence of subchondral BME / osteitis on MRI of SIJ compatible with SpA44.54Presence of BME / osteitis on MRI of spine compatible with SpA455History or current presence of back pain5.55.86History of or current presence of inflammatory back pain5.567Good response of back pain to non-steroidal anti-inflammatory drugs87.88HLA-B2788.19Family history for SpA9.5910Elevated C-reactive protein109.311Presence of peripheral arthritis and/or enthesitis and/or dactylitis109.412Presence of anterior uveitis109.513Presence of inflammatory bowel disease109.6BME=bone marrow edema, MRI=magnetic resonance imaging, SIJ=sacroiliac joints, SpA=spondyloarthritisDisclosure of Interests:Denis Poddubnyy Grant/research support from: AbbVie, MSD, Novartis, and Pfizer, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Filip van den Bosch Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Juergen Braun Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Eli Lilly and Company, Medac, MSD (Schering Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi- Aventis, and UCB Pharma, Consultant of: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Alice Gottlieb Grant/research support from: Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, Consultant of: AbbVie, Allergan, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, BMS, Celgene, Dermira, Incyte, Eli Lilly, Janssen, LEO Pharma, Novartis, Reddy Labs, Sun Pharmaceutical Industries, UCB, Valeant, Xbiotech, Laura C Coates: None declared, Vinod Chandran Grant/research support from: Abbvie, Celgene, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lily, Janssen, Novartis, Pfizer, UCB, Employee of: Spouse employed by Eli Lily, Philip Helliwell: None declared, Deepak Jadon: None declared, Joachim Sieper Consultant of: AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, and UCB Pharma, Speakers bureau: AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, and UCB Pharma, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead Sciences, Inc., Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma; Director of Imaging Rheumatology BV, Dafna D Gladman Grant/research support from: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – consultant
8
Gottlieb, A. B., F. Behrens, P. Nash, J. F. Merola, K. Ding, P. Pellet, L. Pricop, and I. Mcinnes. "FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 763.2–764. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4736.
Full textAbstract:
Background:Psoriatic arthritis (PsA) is a heterogeneous disease comprising musculoskeletal and dermatological manifestations, especially plaque psoriasis.1Secukinumab (SEC), an IL-17A inhibitor, provided significantly greater PASI 75/100 responses in a head-to-head trialversus (vs.) etanercept, a TNF inhibitor, in patients (pts) with moderate-to-severe plaque psoriasis.2The objective of the EXCEED study (NCT02745080) was to investigate whether SEC is superior to adalimumab (ADA), a TNF inhibitor, as monotherapy in biologic-naive active PsA pts with active plaque psoriasis (defined as having at least one psoriatic plaque of ≥2 cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis).Objectives:To report the pre-specified skin outcomes from the EXCEED study in the subset of pts with at least 3% body surface area (BSA) affected with psoriasis at baseline.Methods:Head-to-head, phase-3b, randomised, double-blind, active-controlled, multicentre, parallel-group trial: pts were randomised to receive SEC 300 mg subcutaneous at baseline, Week 1-4, followed by dosing every 4 weeks (q4w) until Week 48 or ADA 40 mg subcutaneous at baseline followed by same dosing q2w until Week 50. The primary endpoint was superiority of SECvs.ADA on ACR20 response at Week 52. Pre-specified outcomes included the proportion of pts achieving a combined ACR50 and PASI 100 response, PASI 100 response, and absolute PASI score ≤3. Missing data was handled using multiple imputation.Results:853 pts were randomised to receive SEC (n=426) or ADA (n=427). At baseline, there were 215 and 202 pts having at least 3% BSA affected with psoriasis in the SEC and ADA groups, respectively. A higher proportion of patients achieved simultaneous improvement in ACR50 and PASI 100 response with SECvs.ADA (30·7%vs.19·2%; P=0·0087 [Figure]). Higher efficacy was demonstrated for SECvs.ADA for PASI 100 responses and for the proportion of pts achieving absolute PASI score ≤3 (Table).Conclusion:In this pre-specified analysis, SEC provided higher responses compared to ADA in achievement of simultaneous improvement of joint and skin disease (combined ACR50 and PASI 100 response) and in skin specific endpoints (PASI 100 and PASI score ≤3) at Week 52.References:[1]Coates LC and Helliwell PS.Clinical Med.2017;17:65–70.[2]Langley RG et al.N Engl J Med.2014;371:326–38.Figure.Combined ACR50 and PASI 100 Response through Week 52Table.Skin Specific Outcomes at Week 52Endpoints, data is presented as % responseSEC 300 mg(N = 215)ADA 40 mg(N = 202)P-value (unadjusted)PASI 10046·029·70·0007Absolute PASI score ≤379·265·00·0015P value vs. adalimumab; Unadjusted P values are presentedN, number of patients in psoriasis subsetMultiple imputation was used for handling missing dataADA, adalimumab; BSA, body surface area; PASI, psoriasis area severity index; SEC, secukinumabAcknowledgments:Suchita Dubey (Novartis) provided medical writing support.Disclosure of Interests:Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Joseph F. Merola Consultant of: Merck, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB Pharma, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres and LEO Pharma, Kevin Ding Employee of: Novartis, Pascale Pellet Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB
9
Lal, Ashutosh, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, and Sujit Sheth. "Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease." Blood 138, Supplement 1 (November 5, 2021): 4162. http://dx.doi.org/10.1182/blood-2021-145752.
Full textAbstract:
Abstract Background Sickle cell disease (SCD) and thalassemia are inherited hemoglobinopathies characterized by lifelong anemia. In SCD, a single mutation in the β-globin gene results in sickle hemoglobin (HbS) that polymerizes upon deoxygenation, causing red blood cells (RBCs) to sickle leading to a variety of complications. In thalassemia, mutation(s) in α- or β-globin genes result in reduced or absent adult Hb causing ineffective erythropoiesis and downstream complications. The resultant anemias are exacerbated by impaired RBC function due to decreased ATP content. Supportive care and agents like hydroxyurea are used most in SCD, with a subset of patients (pts) on regular transfusions. Regular or episodic transfusions, with their own set of complications, are the mainstay of treatment for thalassemias. Etavopivat, a potent, selective, oral, small molecule activator of erythrocyte pyruvate kinase (PKR) increases ATP and decreases 2,3 diphosphoglycerate (2,3-DPG). In a Phase 1 study, etavopivat 300‒600 mg once daily in pts with SCD not regularly transfused was well-tolerated, improved hematological markers, decreased hemolysis, and improved markers of RBC functional health (Brown et al. EHA 2021 # EP1202). Etavopivat 200 and 400 mg once daily (dose levels predicted to provide the desired pharmacodynamic response profiles) is being evaluated in a Phase 2/3 study of pts with SCD who are not on chronic transfusions (The Hibiscus Study, NCT04624659). Herein we describe the design of a Phase 2, open-label, multicenter study (NCT04987489) evaluating the efficacy and safety of etavopivat in pts with: SCD on chronic transfusions (Cohort A), transfusion-dependent thalassemia (Cohort B), and non-transfusion-dependent thalassemia (Cohort C). Study Design and Methods Up to 20 pts aged 12-65 years will be enrolled in each of the three cohorts described above. Pts will receive etavopivat 400 mg once daily for 48-wks (Figure). In cohorts A and B, pts must have received ≥6 RBC units in the 24 wks before the first dose of etavopivat without a >35-day transfusion-free period during that period and be on iron chelation therapy for >3 months before enrollment. Additionally, pts in Cohort A should have received ≥24 monthly transfusions for the prevention or treatment of primary stroke. Pts in Cohort C should have a Hb ≤10 g/dL. Key exclusion criteria include significant infection, hepatic/renal dysfunction, history of malignancy/cardiac/pulmonary disease, a drug malabsorption disorder, prior/concomitant therapies ≤3 months before the first dose (eg, chronic systemic glucocorticoids, new chelation therapy). Baseline assessments will include medical, disease, transfusion, and medication histories. Transfusions received during the study (every ~3-5 wks) will be recorded and include Hb values before and ≥15 minutes after transfusion, number of RBC units, and volume of packed RBCs. If a pt has an increase in pre-transfusion Hb of ≥1.0 g/dL compared with their baseline pre-transfusion Hb, the Investigator may delay transfusion by 1 wk or reduce the number of RBC units transfused. In pts with SCD, RBC exchange may also be performed. The primary endpoint for Cohorts A/B is erythroid response defined as the proportion of pts with ≥20% reduction in transfusions over a continuous 12-wk treatment period versus baseline, and for Cohort C is Hb response at Wk 12 defined as an increase in Hb of ≥1.0 g/dL from baseline. For Cohorts A/B, secondary and exploratory endpoints include the proportion of pts with a reduction in transfusions over 12 wks of ≥33% and ≥50%, respectively, and a reduction in transfusions over 12, 24, and 48 wks; and for Cohort C, Hb response at Wks 24 and 48, and changes from baseline in Hb over 12, 24, and 48 wks. The following additional endpoints will be assessed for all cohorts: changes from baseline in quality of life as assessed via the Short Form Health Survey and Patient-Reported Outcome Measurement Information System Fatigue Scale; changes from baseline in the levels of serum ferritin at 12, 24, and 48 wks; liver iron at 48 wks; 2,3-DPG and ATP; pharmacokinetics; and safety. All primary endpoints will be analyzed using a 1-sided test at α=0.025. Summary Etavopivat is a novel, investigational, PKR activator designed to improve the functional health of RBCs. This Phase 2 study will assess the safety of etavopivat and its impact on Hb levels and transfusion burden in pts with SCD or thalassemia. Figure 1 Figure 1. Disclosures Lal: Chiesi: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; bluebird bio, Inc.: Research Funding; Protagonist Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios Pharmaceuticals: Consultancy; Insight Magnetics: Research Funding; Novartis: Research Funding; Terumo Corporations: Research Funding; La Jolla Pharmaceutical Company: Research Funding. Brown: Novo Nordisk: Consultancy; Novartis: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Forma Therapeutics: Research Funding; Pfizer: Research Funding; Global Blood Therapeutics: Consultancy, Research Funding. Coates: Apo Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Chiesi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Research Funding; Forma Pharma: Consultancy; Sangamo: Consultancy; UpToDate: Patents & Royalties; Vifor Pharma: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kalfa: Agios Pharmaceuticals, Inc.: Other: Steering Committee, Research Funding; FORMA Therapeutics, Inc: Research Funding. Kwiatkowski: Bioverativ: Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Agios Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; CRISPR: Research Funding; Imara: Consultancy, Research Funding; Silence Therapeutics: Consultancy; Sangamo: Research Funding; bluebird bio: Consultancy, Research Funding; Chiesi: Research Funding; Vertex: Research Funding. Brevard: Forma Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Potter: Forma Therapeutics, Inc: Current Employment, Current equity holder in publicly-traded company; Bristol Myers Squibb: Ended employment in the past 24 months. Wood: Forma Therapeutics, Inc: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. Sheth: Bluebird bio: Consultancy; CRISPR: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Imara: Research Funding; Chiesi: Consultancy; Agios: Consultancy; Dispersol: Research Funding.
10
Ovseiko, P. V., L. Gossec, L. Andreoli, U. Kiltz, L. Van Mens, N. Hassan, M. Van der Leeden, et al. "THU0580 EULAR TASK FORCE ON GENDER EQUITY IN ACADEMIC RHEUMATOLOGY: PRELIMINARY SURVEY FINDINGS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 531.2–532. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3384.
Full textAbstract:
Background:Women represent an increasing proportion of the overall rheumatology workforce, but are underrepresented in academic rheumatology, especially in leadership roles [1].Objectives:The EULAR Task Force on Gender Equity in Academic Rheumatology has been convened to establish the extent of the unmet need for support of female rheumatologists, health professionals and non-clinical scientists in academic rheumatology and develop a framework to address this through EULAR and EMEUNET.Methods:To investigate gender equity in academic rheumatology, an anonymous web-based survey was targeted at the membership of EULAR and Emerging EULAR Network (EMEUNET) and their wider networks. The survey was developed based on a narrative literature review [1], best practice from The Association of Women in Rheumatology, a survey of task force members and face-to-face task force discussions. Personal experiences were explored and 24 potential interventions to aid career advancement were ranked. Statistics were descriptive with significance testing for male/female responses compared using chi-squared/t-tests. The level of significance was set at p<0.001.Results:A total of 301 respondents from 24 countries fully completed the survey. By profession, 290 (86.4%) were rheumatologists, 19 (6.3%) health professionals, and 22 (7.3%) non-clinical scientists. By gender, 217 (72.1%) were women, 83 (27.6%) men, and 1 (0.3%) third gender. By age, 203 (67.5%) were 40 or under. By ethnicity, 30 (10.0%) identified themselves as ethnic minority. A high proportion of respondents reported having experienced gender discrimination (47.2% total: 58.1% for women and 18.1% for men) and sexual harassment (26.2%: 31.8% and 10.8% respectively) (Figure 1). Chi-squared tests on the numbers on which these proportions were based showed statistically significant differences between women and men in having experienced gender discrimination (Χ2=36.959 (df=1), p <0.001) and sexual harassment (Χ2=12.633 (df=1), p <0.001). The highest-ranked interventions for career advancement regardless of respondents’ gender included: leadership skills training; speaking/presentation/communication skills training; information on training/career pathways; effective career planning training; support on grant writing applications; and high-impact scientific writing master-classes (Figure 2). Only 8 of 24 proposed interventions showed a significantly higher ranking (p<0.001) by female respondents and these typically related to promotion of female role models and gender-balance in committees, editorial boards and research funding (Figure 2).Figure 1.Perceived gender discrimination and sexual harassment, 301 responsesFigure 2.Mean perceived utility of potential interventions for career advancement by gender and statistically significant gender differences (p<.001), 300 responsesConclusion:The results of the survey will inform the development of task force policy proposals for interventions to support career advancement among EULAR and EMEUNET members. The identified interventions have potential to support career advancement of all rheumatologists, health professionals and non-clinical scientists regardless of gender.References:[1]Andreoli L, Ovseiko PV, Hassan N, Kiltz U, van Mens L, Gossec L, et al. Gender equity in clinical practice, research and training: Where do we stand in rheumatology? Joint, Bone, Spine: Revue du Rhumatisme. 2019;86(6):669-672.Acknowledgments:We gratefully acknowledge the rheumatologists, health professionals and non-clinical scientists who responded to the survey.Disclosure of Interests:Pavel V Ovseiko: None declared, Laure Gossec Grant/research support from: Lilly, Mylan, Pfizer, Sandoz, Consultant of: AbbVie, Amgen, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis, UCB, Laura Andreoli: None declared, Uta Kiltz Grant/research support from: AbbVie, Amgen, Biogen, Novartis, Pfizer, Consultant of: AbbVie, Biocad, Eli Lilly and Company, Grünenthal, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer, Roche, UCB, Leonieke van Mens: None declared, Neelam Hassan: None declared, Marike van der Leeden: None declared, Heidi J Siddle: None declared, Alessia Alunno: None declared, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Nemanja Damjanov Grant/research support from: from AbbVie, Pfizer, and Roche, Consultant of: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Speakers bureau: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Florence Apparailly: None declared, Caroline Ospelt Consultant of: Consultancy fees from Gilead Sciences., Irene van der Horst-Bruinsma Grant/research support from: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Consultant of: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Elena Nikiphorou: None declared, Katie Druce Speakers bureau: Pfizer and Lilly, Zoltán Szekanecz Grant/research support from: Pfizer, UCB, Consultant of: Sanofi, MSD, Abbvie, Pfizer, Roche, Novertis, Lilly, Gedeon Richter, Amgen, Alexandre Sepriano: None declared, Tadej Avcin: None declared, George Bertsias Grant/research support from: GSK, Consultant of: Novartis, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Anne Maree Keenan: None declared, Laura C Coates: None declared
11
Nash, P., M. E. Luggen, L. Espinoza, F. J. García Fructuoso, R. C. Chou, A. M. Mendelsohn, S. Rozzo, and I. Mcinnes. "SAT0431 PROPORTIONS OF PATIENTS ACHIEVING A MINIMAL DISEASE ACTIVITY STATE UPON TREATMENT WITH TILDRAKIZUMAB IN A PSORIATIC ARTHRITIS PHASE 2B STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1171.2–1171. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3947.
Full textAbstract:
Background:Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved in the US, EU, and Australia to treat moderate to severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multiple-dose, phase 2b study evaluating the efficacy and safety of TIL was recently completed (NCT02980692).Objectives:To characterise and evaluate the rate of minimal disease activity (MDA) up to week (W)52 from the phase 2b study.Methods:Patients (pts) ≥18 years old with active psoriatic arthritis (PsA)2and ≥3 tender and ≥3 swollen joints were randomised 1:1:1:1:1 to receive TIL 200 mg every 4 weeks (Q4W) to W52, TIL 200 mg Q12W to W52, TIL 100 mg Q12W to W52, TIL 20 mg Q12W to W24→TIL 200 mg Q12W to W52, or placebo (PBO) Q4W to W24→TIL 200 mg Q12W to W52. MDA was assessed throughout the study; an MDA response was achieved when 5 of 7 criteria were met.3Safety was assessed throughout the study and included treatment-emergent adverse event (TEAE) monitoring.Results:Of 500 pts screened, 391 were randomised and received ≥1 dose of study drug. At baseline (BL), mean age was 48.8 years, 55% were female, 97% were White, mean body mass index was 29.7 kg/m2, and pts had PsA for a median (range) of 4.4 (0–42.8) years since diagnosis. Baseline disease characteristics related to MDA varied little between study arms (Table).By W24, MDA state was achieved in significantly more pts receiving TIL vs PBO (24%–39% vs 7%; p<0.02 for all groups); the proportion further increased with continued TIL treatment to W52 (45%–64%), including pts who switched from PBO to TIL (47%) (Figure).Among the overall pt population from BL→W24/W25→W52, 50.4%/39.9% and 2.3%/1.0% experienced a TEAE and serious TEAE, respectively. From BL→W24, 1 serious infection (chronic tonsillitis) was reported for TIL 20 mg→200 mg Q12W arm. From W25→W52, there was 1 malignancy (TIL 20→200 mg Q12W). There were no reports of candidiasis, uveitis, inflammatory bowel disease, major adverse cardiac events, or deaths from BL→W24 or W25→W52.Table.Baseline disease characteristics related to minimal disease activityTIL 200 mg Q4Wn = 78TIL 200 mg Q12Wn = 79TIL 100 mg Q12Wn = 77TIL 20→200 mg Q12Wn = 78PBO→TIL 200 mg Q12Wn = 79Swollen joint count10.410.011.09.411.8Tender joint count16.619.521.319.019.7Patient GADA score57.861.160.361.965.2Patient pain assessment55.459.659.260.964.2Enthesitis (LEI) score*1.91.52.22.21.5PASI†7.66.28.86.65.0HAQ-DI score1.01.01.01.11.2Data are reported as mean.*Total patients analysed (n) = 76, 79, 76, 78, 78, respectively.†Total patients analysed (n) = 75, 79, 76, 75, 75, respectively.GADA, global assessment of disease activity; HAQ-DI, Health Assessment Questionnaire Disability Index; LEI, Leeds Enthesitis Index; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q4W, every 4 hours; Q12W, every 12 hours; TIL, tildrakizumab.Conclusion:TIL produced clinically meaningful improvement in pts with PsA, resulting in a large proportion of pts achieving MDA by W52, and was well tolerated through W52.References:[1]Reich, et al.Lancet2017;390:276−88.[2]Taylor, et al.Arthritis Rheum2006;54:2665–73.[3]Coates, et al.Ann Rheum Dis2010;69:48−53.Disclosure of Interests:Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Michael E Luggen Grant/research support from: AbbVie; Amgen; Eli Lilly; Genentech; Nichi-Iko; Novartis; Pfizer; R-Pharm; and Sun Pharmaceutical Industries, Inc., Consultant of: AbbVie; Amgen; Eli Lilly; Genentech; Nichi-Iko; Novartis; Pfizer; R-Pharm; and Sun Pharmaceutical Industries, Inc., Speakers bureau: AbbVie; Amgen; Eli Lilly; Genentech; Nichi-Iko; Novartis; Pfizer; R-Pharm; and Sun Pharmaceutical Industries, Inc., Luis Espinoza: None declared, Ferran J García Fructuoso Grant/research support from: AbbVie, Eli Lilly, Gedeon Richter, MedImmune, Nichi-Iko, Pfizer, Sanofi-Aventis, Takeda, and UCB, Consultant of: AbbVie, Eli Lilly, Gedeon Richter, MedImmune, Nichi-Iko, Pfizer, Sanofi-Aventis, Takeda, and UCB, Speakers bureau: AbbVie, Eli Lilly, Gedeon Richter, MedImmune, Nichi-Iko, Pfizer, Sanofi-Aventis, Takeda, and UCB, Richard C Chou Consultant of: Sun Pharmaceutical Industries, Inc, Alan M Mendelsohn Shareholder of: Johnson and Johnson, Employee of: Sun Pharmaceutical Industries, Inc, Stephen Rozzo Employee of: Sun Pharmaceutical Industries, Inc, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB
12
Wang Liangliang, 王亮亮, 张家顺 Zhang Jiashun, 安俊明 An Junming, 李绍洋 Li Shaoyang, 胡炎彰 Hu Yanzhang, and 常夏森 Chang Xiasen. "紧凑低损耗粗波分解复用芯片." Acta Optica Sinica 41, no. 9 (2021): 0923001. http://dx.doi.org/10.3788/aos202141.0923001.
Full text
13
Leung, Y. Y., R. Holland, A. Mathew, C. Lindsay, N. Goel, A. Ogdie, A. M. Orbai, et al. "AB0794 CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FUNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1696.2–1697. http://dx.doi.org/10.1136/annrheumdis-2020-eular.883.
Full textAbstract:
Background:Physical function is a core domain to be measured in randomized controlled trials (RCTs) of psoriatic arthritis (PsA). The discriminative performance of patient reported outcome measures (PROMs) for physical function (PF) in RCTs has not been evaluated systematically.Objectives:In this systematic review, the GRAPPA-OMERACT working group aimed to evaluate the clinical trial discrimination of PF-PROMs in PsA RCTs.Methods:We searched PubMed and Scopus databases in English to identify all original RCTs conducted in PsA. We limited the review to RCTs of biologic and targeted synthetic DMARDs. Groups of two researchers extracted data independently for PF-PROMs. We assessed quality in each article using the OMERACT good method checklist. Effect sizes (ES) for the PF-PROMs were calculated and appraised usinga priorihypotheses. Evidence supporting clinical trial discrimination for each PF-PROM was summarized to derive recommendations.Results:32 articles were included (Figure 1). Four PF-PROMs had data for evaluation: HAQ-Disability Index (DI), HAQ-Spondyloarthritis (S), Short Form 36-item Health Survey Physical Component Summary (SF-36 PCS), and the Physical Functioning domain (SF-36 PF) (Table 1). The ES for intervention versus (vs.) control arms for HAQ-DI ranged from -0.55 to -1.81 vs. 0.24 to -0.52; and for SF-36 PCS ranged from 0.30 to 1.86 vs. -0.02 to 0.63.Table 1.Summary of Measurement Properties Table for clinical trial discriminationArticlesHAQ-DIHAQ-SSF-36 PCSSF-36 PFAntoni 2005 (IMPACT); Gottlieb 2009 (UST)+Antoni 2005 (IMPACT2)++Kavanaugh 2006 (IMPACT2)+Mease 2005 (ADEPT); Genovese 2007 (ADA); Mease 2010 (ETN); Kavanaugh 2009 (GO-REVEAL); Kavanaugh 2017 (GO-VIBRANT); Gladman 2014 (RAPID-PsA); Mease 2015 (FUTURE1); McInnes 2015 (FUTURE2); Kavanaugh, 2016 (FUTURE2)-subgroup; Nash 2018 (FUTURE3); Mease 2017 (SPIRIT-P1); Nash 2017 (SPIRIT-P2); Deodhar 2018 (GUS); Mease 2016 (CLZ)++Mease 2000 (ETN); McInne, 2013 (PSUMMIT 1); Ritchlin 2014 (PSUMMIT 2); Araugo 2019 (ECLIPSA)++Gniadecki 2012 (PRESTA)+Mease 2019 (SEAM-PsA)+/-+McInnes 2014 (SEC)++Mease 2014 (BRO)++Mease 2011 (ABT)+/-+Mease 2017 (ASTRAEA)++Mease 2006 (ALC)+/-Mease 2017 (OPAL Broaden); Gladman 2017 (OPAL Beyond)++Mease 2018 (EQUATOR)++Mease 2018 (ABT-122)+Total available articles311244Total articles for evidence synthesis291232Overall rating+++Color code in each box indicate study quality by OMERACT good methods. GREEN: “likely low risk of bias”; AMBER: “some cautions but can be used as evidence”; RED: “don’t use as evidence”. WHITE (empty boxes): absence of information from that study. (+): findings had adequate performance of the instrument; (+/-): equivocal performance; (-): poor performance (less than adequate).Conclusion:Clinical trial discrimination was supported for HAQ-DI and SF-36 PCS in PsA with low risk of bias; and for SF-36 PF with some caution. More studies are required for HAQ-S.Disclosure of Interests:Ying Ying Leung Speakers bureau: Novartis, Janssen, Eli Lilly, Richard Holland: None declared, Ashish Mathew: None declared, Christine Lindsay Employee of: Previously employed (worked) for pharmaceutical company., Niti Goel Shareholder of: UCB and Galapagos, Consultant of: VielaBio, Mallinckrodt, and IMMVention, Alexis Ogdie Grant/research support from: Novartis, Pfizer – grant/research support, Consultant of: AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda – consultant, Ana-Maria Orbai Grant/research support from: Abbvie, Eli Lilly and Company, Celgene, Novartis, Janssen, Horizon, Consultant of: Eli Lilly; Janssen; Novartis; Pfizer; UCB. Ana-Maria Orbai was a private consultant or advisor for Sun Pharmaceutical Industries, Inc, not in her capacity as a Johns Hopkins faculty member and was not compensated for this service., Pil Hoejgaard: None declared, Jeffrey Chau: None declared, Laura C Coates: None declared, Vibeke Strand: None declared, Dafna D Gladman Grant/research support from: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – consultant, Robin Christensen: None declared, William Tillett: None declared, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau
14
Porras, Simo P., Minna Hartonen, Jani Koponen, Katriina Ylinen, Kyösti Louhelainen, Jarkko Tornaeus, Hannu Kiviranta, and Tiina Santonen. "Occupational Exposure of Plastics Workers to Diisononyl Phthalate (DiNP) and Di(2-propylheptyl) Phthalate (DPHP) in Finland." International Journal of Environmental Research and Public Health 17, no. 6 (March 19, 2020): 2035. http://dx.doi.org/10.3390/ijerph17062035.
Full textAbstract:
The aim of this study was to assess occupational exposure to diisononyl phthalate (DiNP) and di(2-propylheptyl) phthalate (DPHP] in Finland. Four companies took part in the research project: A cable factory, a plastic producing company, a producer of coated textiles, and a tarpaulin producer. The cable factory used DPHP (and occasionally also diisodecyl phthalate, DiDP), the plastic producing company used both DPHP and DiNP, and the latter two companies used DiNP in their production. Exposure was assessed by measuring phthalate metabolites in urine samples (biomonitoring) and by performing air measurements. Low-level occupational exposure to DiNP was observed in the company that produced coated textiles—out of eight workers, one extruder operator was exposed to DiNP at levels exceeding the non-occupationally exposed population background levels. Some workers in the cable factory and the plastics producing company were occupationally exposed to DPHP. Air levels of phthalates were generally low, mostly below the limit of quantification. All phthalate metabolite concentrations were, however, well below the calculated biomonitoring equivalents, which suggests that the health risks related to the exposure are low.
15
Chen, Tao, Guo Zhen Wang, Jie Gao, Yan Dan Yang, Rui Ma, Xin Rong Lei, and Chun Jie Yan. "Study on Resin Coated Sand Proppant Used for Oil Production." Advanced Materials Research 524-527 (May 2012): 1910–14. http://dx.doi.org/10.4028/www.scientific.net/amr.524-527.1910.
Full textAbstract:
A method of preparing precured resin coated sand particles was developed. The effects of resins dosages, plasticizer and coupling agent on the sphericity, roundness, crush resistance and flow conductivity of pre-cured resin coated sand were also discussed. Compared with raw sand, the sphericity and roundness of this resin coated sand particles is higher. It also possessed excellent properties to company sample, such as better resistance to crushing, as well as higher short term flow conductivity. By use of the resin coated sand, the cost could be reduced, and the yield of raw oil will be increased. It is a promising method of modified sand in field of hydraulic fracturing treatment.
16
Mcinnes, I., J. F. Merola, P. J. Mease, L. C. Coates, P. Joshi, J. Coarse, B. Ink, and C. T. Ritchlin. "SAT0403 EFFICACY AND SAFETY OF 108 WEEKS’ BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1153–54. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1850.
Full textAbstract:
Background:Bimekizumab (BKZ), a monoclonal antibody that selectively neutralises IL-17A and IL-17F, has shown clinical improvements in skin and joint outcomes over 48 weeks (wks) in patients (pts) with active psoriatic arthritis (PsA).1Objectives:To report 2-year interim results from a phase 2b dose-ranging study (BE ACTIVE;NCT02969525) and open-label extension (OLE;NCT03347110) of BKZ in pts with PsA.Methods:Design of the dose-ranging study is described elsewhere.1Pts who completed 48 wks’ BKZ treatment without meeting withdrawal criteria were eligible for OLE entry. All OLE pts received BKZ 160 mg Q4W, irrespective of prior dosing regimen.Data are presented from dose-ranging study baseline (BL) to OLE Wk 60 (Wk 108 total). Efficacy outcomes are reported for the full analysis set (FAS): pts who received ≥1 dose BKZ (specifically those randomised to 160 mg, 160 mg with 320 mg loading dose [LD], or 320 mg at BL), with BL efficacy measurements to allow subsequent determination of ACR50. Outcomes include ACR20/50/70, body surface area (BSA) 0%, minimal disease activity (MDA), and enthesitis/dactylitis resolution. Rates of treatment-emergent adverse events (TEAEs) are reported for the Safety Set (SS; pts who received ≥1 dose BKZ in the dose-ranging study).Results:BL mean (SD) tender/swollen joint counts were 21.7 (15.7) and 11.2 (8.4). 80 (65.0%) pts had BSA ≥3% and dactylitis/enthesitis were present in 41 (33.3%) and 68 (55.3%) pts. Over 108 wks’ BKZ treatment, improvements were observed in skin/joint outcomes: ACR50 (66.7%), BSA 0% (75.4%), MDA (65.6%), and resolution of dactylitis (65.9%) and enthesitis (77.9%) (Table). Serious TEAEs occurred in 9.3% pts (Table); no deaths or major adverse cardiac events were reported. Oral candidiasis occurred in 16 (7.8%) pts (no serious cases).Conclusion:BKZ leads to long-term efficacy for skin/joint manifestations of PsA, with >50% pts achieving high thresholds of disease control (ACR50, BSA 0%, MDA) after 108 wks’ treatment. The safety profile reflects previous observations.1References:[1]Ritchlin CT. Ann Rheum Dis 2019;78:127–8.Table.Outcomes at OLE Wk 60 (Wk 108 total)BKZ 160 mg[a](N=82)BKZ 320 mg[a](N=41)BKZ total(N=123)OCNRIOCNRIOCNRIEfficacy (FAS)n (%)ACR2053/62 (85.5)53 (64.6)29/37 (78.4)29 (70.7)82/99 (82.8)82 (66.7)ACR5041/62 (66.1)41 (50.0)25/37 (67.6)25 (61.0)66/99 (66.7)66 (53.7)ACR7034/62 (54.8)34 (41.5)19/37 (51.4)19 (46.3)53/99 (53.5)53 (43.1)BSA 0% [b]35/42 (83.3)–14/23 (60.9)–49/65 (75.4)–MDA [c]43/61 (70.5)43 (52.4)20/35 (57.1)20 (48.8)63/96 (65.6)63 (51.2)Dactylitis resolution–16/27 (59.3)–11/14 (78.6)–27/41 (65.9)Enthesitis resolution [c]–34/45 (75.6)–19/23 (82.6)–53/68 (77.9)Safety (SS)n (%) [EAER]BKZ 160 mg[d](N=198)BKZ 320 mg[d](N=80)BKZ total[d, e](N=204)Any TEAE163 (82.3) [160.9]57 (71.3) [299.8]179 (87.7) [181.1]Study discontinuation due to TEAEs17 (8.6)1 (1.3)18 (8.8)Permanent withdrawal of study drug due to TEAEs16 (8.1)2 (2.5)18 (8.8)Drug-related TEAEs72 (36.4)29 (36.3)92 (45.1)Serious TEAEs19 (9.6) [4.8]019 (9.3) [4.1][a] BKZ 160 mg pts received this dose continuously to Wk 108 (includes those originally assigned to 160 mg with LD); BKZ 320 mg pts were dose-reduced to 160 mg at OLE entry; [b] Pts with BSA ≥3% at BL; [c] Data from OLE Wk 72 (Wk 120 total); [d] Dose received at TEAE onset (pts may be counted in multiple columns); [e] Includes pt time on BKZ 16 mg. EAER: exposure-adjusted event rate; NRI: non-responder imputation; OC: observed case.Acknowledgments:This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.Disclosure of Interests:Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Joseph F. Merola Consultant of: Merck, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB Pharma, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres and LEO Pharma, Philip J Mease Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer, Sun Pharma, UCB Pharma, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Novartis, Pfizer, UCB Pharma, Laura C Coates: None declared, Paulatsya Joshi Employee of: UCB Pharma, Jason Coarse Employee of: UCB Pharma, Barbara Ink Shareholder of: GlaxoSmithKline and UCB Pharma, Employee of: UCB Pharma, Christopher T. Ritchlin Grant/research support from: UCB Pharma, AbbVie, Amgen, Consultant of: UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, Janssen
17
Jackson, Mark J., Michael D. Whitfield, Chengying Xu, and Waqar Ahmed. "Diamond coated microtools for machining compact bone." International Journal of Nano and Biomaterials 2, no. 6 (2009): 505. http://dx.doi.org/10.1504/ijnbm.2009.028340.
Full text
18
Duru, KB, R. Uche, OO Obiukwu, DA Ekpechi, and KC Chukwuemeka. "Minimization of Root Causes of Declining Productivity in a Manufacturing Company: A Case Study of Jocalis Company." International Journal of Advanced Multidisciplinary Research and Studies 4, no. 1 (February 14, 2024): 1095–104. http://dx.doi.org/10.62225/2583049x.2024.4.1.2346.
Full textAbstract:
This presents a comprehensive methodology employed to identify and address declining productivity issues within the JOCALIS Aluminium Roofing Sheet Manufacturing Company Limited, situated in Onitsha, Nigeria. The study encompasses various manufacturing divisions, with a primary focus on aluminium roofing sheet production of three lines involve in production of red, black, and milk colour coated roofing sheet. The research aims to uncover the root causes of defects in the manufacturing process and develop effective strategies for improvement. Key methods include data collection through interviews, company records, library research, and internet sources, followed by data analysis and root cause identification. From the result obtained, the average availability of critical machine like the roller machine after root cause analysis is increased by 10.62%. Also, the average MTBF (mean time between failure) of the critical machine after root cause analysis is increased by 13.66% and MTTR (mean time to repair) is decreased to 46.42% respectively. The applications and general impact of this study includes enhancing machine availability, reducing downtime, increasing efficiency, optimizing maintenance practices, implementing preventive maintenance schedules, improving equipment diagnostics, and prioritizing root cause analysis to reduce breakdowns.
19
Kim, Dong-Woon. "The British Multinational Enterprise in the United States before 1914: The Case of J. & P. Coats." Business History Review 72, no. 4 (1998): 523–51. http://dx.doi.org/10.2307/3116621.
Full textAbstract:
In this article Dong-Woon Kim continues his investigation of the multinational activities of the British thread-making company, J. & P. Coats. Dr. Kim previously published “J. & P. Coats in Tsarist Russia, 1889-1917” in the winter 1995 edition of this journal (pp. 465-493). Here he explores the experiences of J. & P. Coats in the United States. Coats began selling its thread in the U.S. soon after the company's founding in 1830. From a modest start, it established a system of agencies to sell its own “Coats” brand and, in 1869, began local manufacture of thread in Rhode Island. Through a careful series of direct investments and the development of a flexible managerial structure, Coats eventually came to dominate the American cotton thread market.
20
Sonoda, Tsutomu, Kenji Katou, Insu Jeon, Yasuo Yamada, and Tadashi Asahina. "Fabrication of Sintered Compact from Aluminum Powder Coated with Tin Deposits by Magnetron DC Sputtering." Materials Science Forum 530-531 (November 2006): 353–57. http://dx.doi.org/10.4028/www.scientific.net/msf.530-531.353.
Full textAbstract:
Fabrication of sintered compact from aluminum powder coated with tin deposits was examined, in order to enhance the bonding among the aluminum particles under the assistance of tin and thereby the sintering effect of the aluminum powder, aiming at improving the mechanical properties of sintered aluminum materials. For the coating of aluminum powder with tin deposits, the deposition of pure tin onto the aluminum particles was carried out by magnetron DC sputtering during the self-convective motion of the aluminum powder in a vacuum chamber. The tablet consisting of the aluminum powder coated with tin deposits was sintered at 650°C in a vacuum chamber for 2 hours, while the tablet consisting of non-coated aluminum powder was also sintered under the same condition for comparison. The sintered compact from the coated aluminum powder was solid and uniform, and its consolidation reached over 95% while that from non-coated aluminum powder was around 85%. According to tensile tests, the tensile strength of the sintered compact from the coated aluminum powder was 75.4N/mm2 while that from non-coated aluminum powder was 71.0N/mm2, and the elongation of the sintered compact from the coated aluminum powder reached over 20% while that from non-coated aluminum powder was around 10%. Therefore it was found that the consolidation and the mechanical properties of the sintered compact consisting of aluminum powder were considerably improved by this powder coating process.
21
Altındiş, Mustafa, Mustafa Güden, and Chaoying Ni. "Sol-derived Hydroxyapatite Ddip-coating of a Porous Ti6Al4V Powder Compact." Eurasian Chemico-Technological Journal 11, no. 2 (April 6, 2016): 12. http://dx.doi.org/10.18321/ectj306.
Full textAbstract:
<p>A sintered porous Ti<sub>6</sub>Al<sub>4</sub>V powder compact with a mean pore size of 63 μm and an average porosity of 37±1% was dip-coated at soaking times varying between 1- and 5-minute using a sol-derived calcium Hydrooxyapatite (HA) powder. The coated compacts were heat-treated at 840 <sup>o</sup>C. The coating thickness was found to increase with increasing soaking time, from 1.87 μm at 1-minute soaking to 9 μm at 5-minute soaking on the average. It was shown that at increasing soaking times, the originally open pores started to close, while at low soaking times the Ti<sub>6</sub>Al<sub>4</sub>V particles were partially coated. The coating layer was shown to be nanoporous and the depth of coating was observed to be relatively shallow: only few particles near the compact surface were HA-coated.</p>
22
Hansen, R. L., T. S. Jørgensen, A. Egeberg, N. Lippert Rosenoe, M. Skougaard, Z. R. Stisen, L. Dreyer, and L. E. Kristensen. "POS1018 DRUG SURVIVAL AND TREATMENT RESPONSE RATES IN PSORIATIC ARTHRITIS PATIENTS SWITCHING TO FIRST- OR SECOND-LINE IL-17 INHIBITOR TREATMENT: A DANISH POPULATION-BASED COHORT STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 819–20. http://dx.doi.org/10.1136/annrheumdis-2022-eular.921.
Full textAbstract:
BackgroundPsoriatic arthritis (PsA) is a seronegative spondyloarthropathy associated with psoriasis [1]. It is defined as a multifaceted chronic inflammatory disease with chronic peripheral and/or axial arthritis, enthesopathy and dactylitis. PsA patients also experience fatigue, decreased physical functions and sleep disturbances, which may result in impaired social activity and decreased work productivity [2, 3]. All of these disease associated symptoms can cause substantial functional and mental impairment and thereby result in decreased quality of life [4-5]. Patient impacting factors are important when trying to further understand the disease and when choosing a treatment option to properly manage the symptoms of PsA [2].ObjectivesThe objective of this study was to assess the effectiveness of switching to a first- or second-line IL-17 inhibitor treatment in patients with PsA from 2014 to 2021, using data from the Danish Rheumatology registry (DANBIO) by investigating drug survival and treatment response rates.MethodsPsA patients recorded in DANBIO who switched to a first- or second-line IL-17 inhibitor treatment from a previous biologic disease-modifying antirheumatic drugs (bDMARD) between 2014 and 2021 were included in this study. Baseline characteristics were analyzed in subgroups: first-line IL-17 inhibitor treatment and second-line IL-17 inhibitor treatment and presented as median and interquartile ranges or number and percentage. Visual analog scale (VAS) fatigue 50% improvement and VAS pain 50% improvement, Disease Activity Scores-28 C-reactive protein (DAS-28-CRP) remission and ΔDAS28 scores at 6- and 12-months follow-up was reported. Drug survival of first- or second-line IL-17 inhibitor treatment was reported as a Kaplan Meier plot.Results583 patients were identified and included in the study. Baseline characteristics (Table 1) showed that the age, percentage of females, CRP, HAQ, VAS patient pain, VAS global and DAS28CRP in both first- and second-line IL-17 inhibitor treatment was comparable. First- and second-line IL-17 inhibitor treatment had almost identical drug survival (Figure 1).Table 1.First-line IL-17 inhibitor n= 434Second-line IL-17 inhibitor n= 97Age, years51.0 (49.6-52.3)51.9 (46.4-54.7)Female, % (n)59.0 (256)53.6 (52)Disease duration, years6.8 (6.1-7.8)8.2 (6.5-12.6)CRP, mg/dl4.0 (4.0-5.2)3.0 (2.9-5.3)HAQ1.1 (1.1-1.3)1.0 (0.9-1.3)VAS pain, 100 mm68 (65-72)73 (66-76)VAS global, 100 mm75 (73-78)80 (75-88)DAS28-CRP4.0 (3.8-4.1)4.2 (3.7-4.6)Previous bDMARD2.0 (1.0-3.0)4.0 (2.0-5.5)CRP: C-reactive protein, HAQ: Health Assessment Questionnaire, VAS: Visual analog scale, DAS28: 28-joint Disease Activity Score, DMARD: disease-modifying antirheumatic drug.Figure 1.ConclusionPsA patients switching to a first- or second-line IL-17 inhibitor showed comparable baseline characteristics and an almost identical drug survival. Thus, treatment failure of a first-line IL-17 inhibitor treatment, should not block for a second-line IL-17 inhibitor treatment.References[1]Ritchlin, C.T., R.A. Colbert, and D.D. Gladman, Psoriatic Arthritis. N Engl J Med, 2017. 376(21): p. 2095-6.[2]Ogdie, A., L.C. Coates, and D.D. Gladman, Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford), 2020. 59(Suppl 1): p. i37-i46.[3]Orbai, A.M., et al., International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis, 2017. 76(4): p. 673-680.[4]Kristensen, L.E., et al., Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden. J Rheumatol, 2016. 43(1): p. 81-7.[5]Jørgensen, T.S., et al., Relation Between Fatigue and ACR Response in Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitor Therapy: A Population-based Cohort Study. J Rheumatol, 2020.Disclosure of InterestsRebekka L. Hansen: None declared, Tanja Schjødt Jørgensen Speakers bureau: AbbVie, Pfizer, Roche, Novartis, UCB, Biogen and Eli Lilly, Consultant of: AbbVie, Pfizer, Roche, Novartis, UCB, Biogen and Eli Lilly, Alexander Egeberg Speakers bureau: AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals, Consultant of: AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals, Grant/research support from: Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, Nana Lippert Rosenoe: None declared, Marie Skougaard Grant/research support from: Eli Lilly and Pfizer, Zara Rebecca Stisen: None declared, Lene Dreyer Speakers bureau: MSD, UCB and Janssen Pharmaceuticals, Consultant of: MSD, UCB and Janssen Pharmaceuticals, Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals, Consultant of: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals
23
Xinyong Dong, Yan Zhou, Wenjun Zhou, Jia Cheng, and Zhongdi Su. "Compact Anemometer Using Silver-Coated Fiber Bragg Grating." IEEE Photonics Journal 4, no. 5 (October 2012): 1381–86. http://dx.doi.org/10.1109/jphot.2012.2208946.
Full text
24
Wang, C. M. "High green compact strength of coated Si3N4 powder." Journal of Materials Science Letters 14, no. 18 (September 1995): 1256–59. http://dx.doi.org/10.1007/bf01262260.
Full text
25
Czapliński, Paweł, and Anna Stawarska. "Przejawy procesu globalizacji w sferze produkcji na przykładzie Scania Production Słupsk S. A." Studies of the Industrial Geography Commission of the Polish Geographical Society 16 (January 1, 2010): 176–86. http://dx.doi.org/10.24917/20801653.16.15.
Full textAbstract:
The article describes the structure of Scania as a global corporation. The company manufactures: city buses, coaches and heavy-load trucks. The article depicts the development of Scania in the world and mainly in Poland. We have described in detail the company from Słupsk – Scania Production Słupsk S.A. Mainly, employment figures and structures, production in numbers, as well as target markets. The part of work concerns the strategy of the company and the plans for further expansion.
26
Frick, Malin, Marléne Isaksson, Bert Björkner, Monica Hindsén, Ann Pontén, and Magnus Bruze. "Occupational allergic contact dermatitis in a company manufacturing boards coated with isocyanate lacquer." Contact Dermatitis 48, no. 5 (May 2003): 255–60. http://dx.doi.org/10.1034/j.1600-0536.2003.00107.x.
Full text
27
Coates, L., R. B. M. Landewé, I. Mcinnes, C. T. Ritchlin, A. B. Gottlieb, A. M. Orbai, R. B. Warren, et al. "AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1775–76. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1671.
Full textAbstract:
BackgroundPsoriatic arthritis (PsA) is a disease characterised by heterogeneous joint and skin manifestations, so comprehensive treatment efficacy is best captured by assessment of a broad spectrum of affected domains using composite outcome measures.[1]Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy and tolerability to 16 weeks (wks) vs placebo (PBO) in patients (pts) with active PsA in the phase 3 BE OPTIMAL and BE COMPLETE studies.[2,3]ObjectivesTo assess the long-term efficacy of BKZ treatment on disease activity using composite outcome measures in pts with active PsA and prior inadequate response or intolerance to tumour necrosis factor alpha inhibitors (TNFi-IR).MethodsBE COMPLETE (NCT03896581) comprised a 16-wk double-blind, PBO-controlled period. Pts with PsA and TNFi-IR were randomised 2:1 to subcutaneous BKZ 160 mg every 4 wks or PBO. Pts who completed Wk 16 were eligible for entry into BE VITAL (NCT04009499), an open-label extension (OLE) study. Pts receiving PBO switched to BKZ at Wk 16 (PBO/BKZ). The BE VITAL OLE included pts from BE OPTIMAL and BE COMPLETE. Here, we report data up to 1 year for pts randomised at baseline (Wk 0) of BE COMPLETE (52 wks of study drug).Composite measure data up to Wk 52 are reported: minimal and very low disease activity (MDA/VLDA), the composite endpoint of ≥50% improvement in American College of Rheumatology criteria and 100% improvement in Psoriasis Area and Severity Index response (ACR50+PASI100) in pts with baseline psoriasis (≥3% body surface area [BSA]), Disease Activity Index for Psoriatic Arthritis (DAPSA), and Psoriatic Arthritis Disease Activity Score (PASDAS; collected up to Wk 40). Missing data were imputed using non-responder imputation (NRI) or worst-category imputation.Results388/400 (97.0%) pts completed Wk 16 of BE COMPLETE; 377 (94.3%) entered BE VITAL and 347 (86.8%) completed Wk 52.At Wk 16, a higher proportion of BKZ-treated pts achieved composite disease activity thresholds vs PBO-treated pts. Across all composite outcome measures, efficacy was sustained to Wk 52 in pts randomised to BKZ treatment at Wk 0, and pts who switched to BKZ at Wk 16 demonstrated improvements in efficacy responses to Wk 52 (Figure 1,Table 1). At Wk 16, 6.0% PBO and 44.2% BKZ pts achieved MDA; at Wk 52, this proportion was sustained on BKZ treatment: 33.1% PBO/BKZ and 47.2% BKZ (NRI;Figure 1). Improved or sustained responses were also observed for the proportions of PBO/BKZ and BKZ pts achieving VLDA, ACR50+PASI100, DAPSA and PASDAS thresholds at Wk 52 (Figure 1;Table 1).ConclusionBKZ-treated pts with PsA and TNFi-IR demonstrated clinically meaningful improvements in composite measures of disease activity, comprising joint and skin domains, vs PBO at Wk 16. These improvements were sustained up to 1 year on BKZ. Pts who switched to BKZ at Wk 16 showed improvements in efficacy responses up to 1 year.Reference[1] Coates LC. Rheum Dis Clin North Am 2015;41(4):699–710;2.McInnes IB. Lancet 2022; DOI: 10.1016/S0140-6736(22)02302-9.3.Merola JF. Lancet 2022; DOI: 10.1016/S0140-6736(22)02303-0.Table 1.Pts achieving composite endpoints at Wk 16 and to Wk 52Wk 16Wk 52n (%)PBO N=133BKZ 160 mg Q4W N=267PBO/BKZ 160 mg Q4W N=133BKZ 160 mg Q4W N=267VLDA[NRI]3 (2.3)36 (13.5)20 (15.0)63 (23.6)Wk 16Wk 40aPASDAS REM+LDA[WCI]14 (10.5)126 (47.2)53 (39.8)146 (54.7)PASDAS REM[WCI]2 (1.5)51 (19.1)22 (16.5)69 (25.8)Randomised set. [a] Data not collected at Wk 52.AcknowledgementsThis study was funded by UCB Pharma. Medical writing support was provided by Costello Medical, funded by UCB Pharma.Disclosure of InterestsLaura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, medac, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Domain, Eli Lilly, Gilead, Galapagos, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer and UCB Pharma, Robert B.M. Landewé Consultant of: AbbVie, AstraZeneca, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie, Pfizer, Novartis and UCB Pharma, Employee of: Owner of Rheumatology Consultancy BV, an AMS company under Dutch law, Iain McInnes Consultant of: AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Cabaletta, Causeway Therapeutics, Celgene, Eli Lilly, Evelo, Janssen, MoonLake, Novartis and UCB Pharma, Grant/research support from: BMS, Boehringer Ingelheim, Celgene, Janssen, Novartis and UCB Pharma, Christopher T. Ritchlin Consultant of: Amgen, AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie, Alice B Gottlieb Consultant of: Honoraria as an advisory board member, non-promotional speaker or consultant for Amgen, AnaptysBio, Avotres Therapeutics, BMS, Boehringer Ingelheim, Dermavant, DiCE Therapeutics, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma and XBiotech (stock options for an RA project), Grant/research support from: AnaptysBio, BMS, Janssen, Novartis, Ortho Dermatologics, Sun Pharma and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai, Ana-Maria Orbai Consultant of: BMS, Janssen, Sanofi and UCB Pharma, Grant/research support from: Research grants to Johns Hopkins University from AbbVie, Amgen and Janssen, Richard B. Warren Consultant of: AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma. Honoraria from Astellas, DiCE, GSK and Union, Grant/research support from: Research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis and UCB Pharma. RBW is supported by the NIHR Manchester Biomedical Centre., Barbara Ink Shareholder of: AbbVie, GSK and UCB Pharma, Employee of: UCB Pharma, Rajan Bajracharya Shareholder of: UCB Pharma, Employee of: UCB Pharma, Jason Coarse Shareholder of: UCB Pharma, Employee of: UCB Pharma, Joseph F. Merola Consultant of: AbbVie, Amgen, Biogen, BMS, Dermavant, Eli Lilly, Janssen, LEO Pharma, Pfizer, Novartis, Regeneron, Sanofi, Sun Pharma and UCB Pharma, Grant/research support from: AbbVie, Amgen, Biogen, BMS, Dermavant, Eli Lilly, Janssen, LEO Pharma, Pfizer, Novartis, Regeneron, Sanofi, Sun Pharma and UCB Pharma.
28
Orbai, A. M., L. C. Coates, A. Deodhar, P. Helliwell, C. T. Ritchlin, A. Kollmeier, E. C. Hsia, et al. "AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1708.1–1709. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2929.
Full textAbstract:
Background:Patients (pts) with psoriatic arthritis (PsA) experience broad systemic symptoms including pain, fatigue, depression, sleep disturbance, poor physical function, and diminished social participation.Objectives:DISCOVER 1 is a Phase 3 trial (NCT03162796) evaluating the efficacy and safety of guselkumab (GUS), an anti-interleukin 23 inhibitor that binds to the p19-subunit of IL-23, in pts with active PsA. PROMIS-29 (Patient-Reported Outcomes Measurement Information System-29), a validated generic health instrument,1assessed the treatment effect of GUS on symptoms in pts with PsA.Methods:Pts with active PsA despite nonbiologic DMARDs were enrolled, and ~30% of pts could have previously received ≤2 TNFi. Pts were randomized (1:1:1) to subcutaneous GUS 100 mg at Week 0 (W0), W4 then q8W (n=127), GUS 100 mg q4W (n=128), or PBO (n=126). Concomitant stable use of select csDMARDs, oral steroids, and NSAIDs was allowed. PROMIS-29 consists of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Social Participation) and a pain intensity 0-10 numeric rating scale (NRS). The raw score of each domain is converted into a standardized T-score with a mean of 50 (general population mean) and a standard deviation (SD) of 10. Higher PROMIS scores represent more of the concept being measured. A >= 5-point improvement (1/2 SD of T-score) is defined as clinically meaningful.1Results:At baseline, mean PROMIS-29 T-scores for physical function, social participation, sleep disturbance, pain, and fatigue were worse than the general US population. At W24, GUS q8W-treated pts achieved greater improvements from baseline in all PROMIS-29 domains vs PBO (p<0.05) (Table and Fig 1). Results were consistent in the GUS q4W group except for anxiety and sleep disturbance. More pts receiving GUS achieved clinically meaningful improvement vs PBO except for depression and anxiety in the GUS q4W group, which were numerically improved (Fig 2).Conclusion:Active PsA pts treated with GUS achieved clinically meaningful reduction in symptoms and improvement in physical function and social participation vs PBO at W24.References:[1]http://www.healthmeasures.net/score-and-interpret/interpret-scores/meaningful-change/165-meaningful-changeTable.PROMIS-29 Domain T-Scores Least Square (LS) Mean Change from BaselineLS Mean Change from BaselinePBOGUS q8WGUS q4WAnxiety-1.37-3.23*-2.92Depression-0.85-3.4**-2.67*Fatigue-1.86-4.79**-5.08**Pain interference-2.30-5.49**-5.69**Physical function1.343.89**5.05**Sleep disturbance-1.17-3.48**-2.46Social participation1.454.90**4.52**Pain intensity-0.56-1.98**-2.32**Nominal p-values vs placebo: *<0.05, **<0.01Acknowledgments:NoneDisclosure of Interests:Ana-Maria Orbai Grant/research support from: Abbvie, Eli Lilly and Company, Celgene, Novartis, Janssen, Horizon, Consultant of: Eli Lilly; Janssen; Novartis; Pfizer; UCB. Ana-Maria Orbai was a private consultant or advisor for Sun Pharmaceutical Industries, Inc, not in her capacity as a Johns Hopkins faculty member and was not compensated for this service., Laura C Coates: None declared, Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Philip Helliwell: None declared, Christopher T. Ritchlin Grant/research support from: UCB Pharma, AbbVie, Amgen, Consultant of: UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, Janssen, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Elizabeth C Hsia Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Shihong Sheng Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Bei Zhou Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Chenglong Han Employee of: Janssen Research & Development, LLC
29
Morris, R. N., and P. J. Pappano. "Estimation of maximum coated particle fuel compact packing fraction." Journal of Nuclear Materials 361, no. 1 (March 2007): 18–29. http://dx.doi.org/10.1016/j.jnucmat.2006.10.017.
Full text
30
Wei, He, Numpon Insin, Jungmin Lee, Hee-Sun Han, Jose M. Cordero, Wenhao Liu, and Moungi G. Bawendi. "Compact Zwitterion-Coated Iron Oxide Nanoparticles for Biological Applications." Nano Letters 12, no. 1 (December 20, 2011): 22–25. http://dx.doi.org/10.1021/nl202721q.
Full text
31
Tamarit-López, Jesús, Sergi Morais, Rosa Puchades, and Ángel Maquieira. "Use of polystyrene spin-coated compact discs for microimmunoassaying." Analytica Chimica Acta 609, no. 1 (February 2008): 120–30. http://dx.doi.org/10.1016/j.aca.2007.12.028.
Full text
32
Yamada, Yutaka, Teruo Izumi, and Yuh Shiohara. "Progress of YBCO Coated Conductor in JAPN and Recent Advance of PLD and IBAD Method." Advances in Science and Technology 47 (October 2006): 124–30. http://dx.doi.org/10.4028/www.scientific.net/ast.47.124.
Full textAbstract:
In the present 5-year national project since 2003, the development of YBCO coated conductors (CC) has advanced rapidly. The high performance processing group of SRL-ISTEC and Fujikura Ltd. has been working on the long tape of the PLD-YBCO superconductor on the IBAD-Gd2Zr2O7 buffered substrate tape. Very recently the SRL group achieved the highest value on the product of Ic x L in the world, 51,940 Am (212 m x 245 A). Fujikura Ltd. also realized the longest buffered substrate tape of 500m long IBAD tape and obtained a 200 m long coated conductor with Ic value of 88 A. In the low cost processing group using MOD, CVD and so on, the high Ic value of 525 A was obtained by SRL using the TFA-MOD method on the IBAD substrate. The 45m long TFA-MOD tape was also obtained with the Ic value of 155 A by Showa Electric Wire and Cable Company. Similarly 100- 200 m class long tapes were also obtained by the MOCVD (Chubu Power Electric Company) and PLD-HoBCO processes (Sumitomo Electric Industry Ltd.). Both groups above are further developing for the final goal of 500 m long tapes with the Ic of 300 A/cm-w at the production rate of 5 m/h. Furthermore, the feasibility study for the application has started due to the above success of long tape production. Several kinds of preliminary experiments using long coated conductors are now in progress for the power applications such as (1) Power Cable, (2) Transformer, (3) Motor and so on.
33
Zhu, Fu Yun, Zhi Hui Lu, Hong Jun Ni, Shuai Shuai Lv, and Xing Xing Wang. "Developed of High Voltage Bushing with New Shielding Technology for High Voltage Switch Cabinet." Applied Mechanics and Materials 737 (March 2015): 247–51. http://dx.doi.org/10.4028/www.scientific.net/amm.737.247.
Full textAbstract:
TGZ10A-40.5 wall bushing of high voltage switch cabinet from one company was taken as applied research object. Reference the development process of high voltage cable shielding technology, three samples were designed and produced depending on different sets of the shield system. The result show that: surfaces processed by the way that the inner (aluminum cylinder) and the outer (metal mesh ring) shielding components were coated with a semi-conductive material, made little sense to improve the withstand voltage level and reduce the partial discharge; surface processed by the way that inner shield component (aluminum cylinder) was coated with semi-conductive material, the outer shield component (metal mesh ring) was not coated with semi-conductive material, was obviously influenced the improvement of the withstand voltage level and reduction of the partial discharge, compared with traditional technology, the average start voltage of corona increased 23.8%, the average value of partial discharge dropped 27.7%.
34
Utami, Christina Whidya, and Kent Adriel Sputra. "The Effectiveness of Promoting Tennis School Training Services Towards Consumer Interest in Tennis in Indonesia." Mediterranean Journal of Social Sciences 8, no. 3 (May 24, 2017): 225–31. http://dx.doi.org/10.5901/mjss.2017.v8n3p225.
Full textAbstract:
Abstract Tennis School is a tennis training service aimed at increasing the popularity of tennis. One of the problems faced by the company is ineffective promotions. This study aims to find the effective promotion strategy for Tennis School. This research is a qualitative research with semi-structured interview as data collection method. Purposive sampling is used to select research informants. The result of this study indicates that in order to attract attention, generate interest, or trigger the desire and action of the consumers, the company can use professional or famous coaches, expand the consumer's knowledge, provide feedback, show the advantages of training through the coaches' knowledge and integrity, and offer free trials to new consumers. Additionally, the company's promotions should focus on the tennis communities, because tennis is a communityoriented sport.
35
Dong-Woon Kim. "J. & P. Coats, the British Cotton Thread Making Company, in Brazil before 1945." Review of Business History 30, no. 4 (December 2015): 255–72. http://dx.doi.org/10.22629/kabh.2015.30.4.011.
Full text
36
Kim, Dong-Woon. "From a Family Partnership to a Corporate Company: J. & P. Coats, Thread Manufacturers." Textile History 25, no. 2 (January 1994): 185–225. http://dx.doi.org/10.1179/004049694793711943.
Full text
37
Rohollahi, A., S. Khatir, C. Xiao, and A. Hirose. "Interaction between the compact tori and coated stainless-steel samples." Radiation Effects and Defects in Solids 172, no. 1-2 (February 2017): 119–26. http://dx.doi.org/10.1080/10420150.2017.1287185.
Full text
38
Jung, Yei Hwan, Yijie Qiu, Subin Lee, Ting-Yen Shih, Yuehang Xu, Ruimin Xu, Juhwan Lee, et al. "A Compact Parylene-Coated WLAN Flexible Antenna for Implantable Electronics." IEEE Antennas and Wireless Propagation Letters 15 (2016): 1382–85. http://dx.doi.org/10.1109/lawp.2015.2510372.
Full text
39
Wang, Junfeng, Jing Shi, Decheng Tian, Hong Deng, Yadong Li, Pengyun Song, and Chinping Chen. "Fabrication and enhanced magnetoresistance of SiO2-coated Fe3O4 nanosphere compact." Applied Physics Letters 90, no. 21 (May 21, 2007): 213106. http://dx.doi.org/10.1063/1.2741612.
Full text
40
Hatano, S., T. Kokubun, Shin Sumida, and Y. Katsuyama. "Optical coupling between coated fibers in a compact fiber ribbon." Journal of Lightwave Technology 4, no. 3 (1986): 335–40. http://dx.doi.org/10.1109/jlt.1986.1074719.
Full text
41
Garro-Piña, Hazel, María Cristina Jiménez-Cervantes, Ricardo Ondarza-Rovira, Roberto Justus, and Salvador García-López. "Evaluation of the Loading, Unloading, and Permanent Deformation of Newly Available Epoxy Resin Coated Ni-Ti Wires Using Self-Ligating Brackets." International Journal of Dentistry 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/8085067.
Full textAbstract:
Aim. The purpose of this study was to evaluate the load and unload deflection and permanent deformation of round 0.016′′ and rectangular 0.016′′×0.022′′ regular and coated Ni-Ti wires. Materials and Methods. Ni-Ti archwires produced by two manufacturers were evaluated. Both regular and coated round and rectangular Ni-Ti wire segments (n=15) from each group were submitted to a three-point bending test. Both types of wires were evaluated for permanent deformation at the end of a recovery cycle. Results. The coated round 0.016′′ Ni-Ti wires produced a significantly lower force in loading (p<0.01) and unloading (p<0.01) than regular wires of the same manufacturer and size. There was no significant difference in permanent deformation between coated and regular round Ni-Ti wires from the same company. For rectangular 0.016×0.022′′ Ni-Ti wires, there was a significant difference in the loading evaluation, but the unloading test presented no significant differences. The permanent deformation of the rectangular wires revealed no significant difference between them. Conclusion. The addition of an esthetic coating to these new Ni-Ti wires produced changes in their mechanical properties, manifested as a reduction in the applied force, which should be considered in clinical management.
42
Ramadhania, Sherin, Iqballulah Iqballulah, and Mislan Mislan. "Analisis Produktivitas Electrolytic Tinning Line dengan Metode Overall Equipment Effectiveness dan Penentuan Kebutuhan Sparepart Komponen Mekanikal Kritis dengan Pendekatan ABC." Jurnal Teknik Industri Terintegrasi 7, no. 3 (July 10, 2024): 1660–72. http://dx.doi.org/10.31004/jutin.v7i3.30897.
Full textAbstract:
A company that produces high quality tinplate with international standards. The product produced is tinplate, namely steel sheets coated with tin. In ETL downtime from May 2022 – April 2023, there is a gap between actual and target downtime, causing the production process to not run optimally, and will cause losses for the company. So it is necessary to determine the effectiveness value of the equipment in ETL and determine the need for spare parts for critical mechanical components. OEE is the magnitude of the effectiveness value of equipment or machines in the Company. ABC classification is a classification of a group of materials in descending order based on the cost of using the material per time period. The results of data processing obtained an average OEE value of 80.06% and for items in class A it was a mechanical seal sink roll. Items in class B are solenoid valve – 48VDC and scotch brite and items in class C are mechanical seal DN 45, filter regulator, bearing 7308DB, bearing NU308EC, and hose assembly.
43
Dong-Woon Kim. "A British Company in British India before 1945: The Case of J. & P. Coats." Journal of Eurasian Studies 9, no. 2 (June 2012): 27–51. http://dx.doi.org/10.31203/aepa.2012.9.2.002.
Full text
44
KITLV, Redactie. "Book Reviews." New West Indian Guide / Nieuwe West-Indische Gids 73, no. 1-2 (January 1, 1999): 121–81. http://dx.doi.org/10.1163/13822373-90002590.
Full textAbstract:
-Charles V. Carnegie, W. Jeffrey Bolster, Black Jacks: African American Seamen in the age of sail. Cambridge MA: Harvard University Press, 1997. xiv + 310 pp.-Stanley L. Engerman, Wim Klooster, Illicit Riches: Dutch trade in the Caribbean, 1648-1795. Leiden: KITLV Press, 1998. xiv + 283 pp.-Luis Martínez-Fernández, Emma Aurora Dávila Cox, Este inmenso comercio: Las relaciones mercantiles entre Puerto Rico y Gran Bretaña 1844-1898. San Juan: Editorial de la Universidad de Puerto Rico, 1996. xxi + 364 pp.-Félix V. Matos Rodríguez, Arturo Morales Carrión, Puerto Rico y la lucha por la hegomonía en el Caribe: Colonialismo y contrabando, siglos XVI-XVIII. San Juan: Editorial de la Universidad de Puerto Rico y Centro de Investigaciones Históricas, 1995. ix + 244 pp.-Herbert S. Klein, Patrick Manning, Slave trades, 1500-1800: Globalization of forced labour. Hampshire, U.K.: Variorum, 1996. xxxiv + 361 pp.-Jay R. Mandle, Kari Levitt ,The critical tradition of Caribbean political economy: The legacy of George Beckford. Kingston: Ian Randle, 1996. xxvi + 288., Michael Witter (eds)-Kevin Birth, Belal Ahmed ,The political economy of food and agriculture in the Caribbean. Kingston: Ian Randle; London: James Currey, 1996. xxi + 276 pp., Sultana Afroz (eds)-Sarah J. Mahler, Alejandro Portes ,The urban Caribbean: Transition to the new global economy. Baltimore: John Hopkins University Press, 1997. xvii + 260 pp., Carlos Dore-Cabral, Patricia Landolt (eds)-O. Nigel Bolland, Ray Kiely, The politics of labour and development in Trinidad. Barbados, Jamaica, Trinidad and Tobago: The Press University of the West Indies, 1996. iii + 218 pp.-Lynn M. Morgan, Aviva Chomsky, West Indian workers and the United Fruit Company in Costa Rica, 1870-1940. Baton Rouge: Louisiana State University Press, 1996. xiii + 302 pp.-Eileen J. Findlay, Maria del Carmen Baerga, Genero y trabajo: La industria de la aguja en Puerto Rico y el Caribe hispánico. San Juan: Editorial de la Universidad de Puerto Rico, 1993. xxvi + 321 pp.-Andrés Serbin, Jorge Rodríguez Beruff ,Security problems and policies in the post-cold war Caribbean. London: :Macmillan; New York: St. Martin's, 1996. 249 pp., Humberto García Muñiz (eds)-Alex Dupuy, Irwin P. Stotzky, Silencing the guns in Haiti: The promise of deliberative democracy. Chicago: University of Chicago Press, 1997. xvi + 294 pp.-Carrol F. Coates, Myriam J.A. Chancy, Framing silence: Revolutionary novels by Haitian women. New Brunswick NJ: Rutgers University Press, 1997. ix + 200 pp.-Havidán Rodríguez, Walter Díaz, Francisco L. Rivera-Batiz ,Island paradox: Puerto Rico in the 1990's. New York: Russel Sage Foundation, 1996. xi + 198 pp., Carlos E. Santiago (eds)-Ramona Hernández, Alan Cambeira, Quisqueya la Bella: The Dominican Republic in historical and cultural perspective. Armonk NY: M.E. Sharpe, 1996. xi + 272 pp.-Ramona Hernández, Emilio Betances ,The Dominican Republic today: Realities and perspectives. New York: Bildner Center for Western Hemisphere studies, CUNY, 1996. 205 pp., Hobart A. Spalding, Jr. (eds)-Bonham C. Richardson, Eberhard Bolay, The Dominican Republic: A country between rain forest and desert. Wekersheim, FRG: Margraf Verlag, 1997. 456 pp.-Virginia R. Dominguez, Patricia R. Pessar, A visa for a dream: Dominicans in the United States. Boston: Allyn and Bacon, 1995. xvi + 98 pp.-Diane Austin-Broos, Nicole Rodriguez Toulis, Believing identity: Pentecostalism and the mediation of Jamaican ethnicity and gender in England. Oxford NY: Berg, 1997. xv + 304 p.-Mary Chamberlain, Trevor A. Carmichael, Barbados: Thirty years of independence. Kingston: Ian Randle Publishers, 1996. xxxv + 294 pp.-Paul van Gelder, Gert Oostindie, Het paradijs overzee: De 'Nederlandse' Caraïben en Nederland. Amsterdam: Bert Bakker, 1997. 385 pp.-Roger D. Abrahams, Richard D.E. Burton, Afro-Creole: Power, Opposition, and Play in the Caribbean. Ithaca NY: Cornell University Press, 1997. x + 297 pp.-Roger D. Abrahams, Joseph Roach, Cities of the dead: Circum-Atlantic performance. New York NY: Columbia University Press, 1996. xiii + 328 pp.-George Mentore, Peter A. Roberts, From oral to literate culture: Colonial experience in the English West Indies. Kingston, Jamaica: The Press University of the West Indies, 1997. xii + 301 pp.-Emily A. Vogt, Howard Johnson ,The white minority in the Caribbean. Princeton NJ: Markus Wiener, 1998. xvi + 179 pp., Karl Watson (eds)-Virginia Heyer Young, Sheryl L. Lutjens, The state, bureaucracy, and the Cuban schools: Power and participation. Boulder CO: Westview Press, 1996. xiii + 239 pp.
45
Coates, L., P. Rahman, P. J. Mease, M. Shawi, E. Rampakakis, A. Kollmeier, X. L. Xu, S. D. Chakravarty, I. Mcinnes, and L. S. Tam. "POS1067 DOMAINS CONTRIBUTING TO MINIMAL DISEASE ACTIVITY ACHIEVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 856–57. http://dx.doi.org/10.1136/annrheumdis-2022-eular.893.
Full textAbstract:
BackgroundDespite effective treatments, a minority of psoriatic arthritis (PsA) patients (pts) realize sustained minimal disease activity (MDA).1 Pt-driven domains of MDA are less frequently achieved, potentially arising from comorbid conditions.1ObjectivesIdentify domains contributing to and factors influencing MDA achievement in the 2-year Phase 3 DISCOVER-2 trial.MethodsRandomized and treated adults (N=739) had active PsA, were biologic/JAK inhibitor-naive, and had swollen and tender joint counts (SJC/TJC) each ≥5 and C-reactive protein ≥0.6 mg/dL. Pts with medical history of fibromyalgia (FM) were not excluded. Pts were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then every 8 weeks (Q8W); or placebo (PBO); PBO pts crossed over to GUS 100 mg Q4W at W24. MDA requires fulfillment of ≥5/7 criteria: TJC ≤1, SJC ≤1, Psoriasis Area and Severity Index (PASI) score ≤1, Pt Pain score ≤15, Pt global disease activity (PtGA) score ≤20, Health Assessment Questionnaire – Disability Index (HAQ-DI) score ≤0.5, and ≤1 tender entheses. A longitudinal trajectory of achieving each MDA criterion through W100 was derived (nonresponder imputation [NRI]). Time to achieve was estimated via Kaplan-Meier survival curve for scores deriving from native scales and those normalized to a 0-66 scale (corresponding to SJC). Multivariate regression models for time to achievement (cox proportional hazard) and achievement (logistic regression) of MDA at W100 identified predictors of response.ResultsAmong 492 GUS pts, continuous improvement across all MDA domains was shown through proportions of pts achieving criteria at W24 & W100 (NRI): SJC (45% & 65%), TJC (16% & 34%), PASI (71% & 72%), Pt Pain (23% & 37%), PtGA (29% & 45%), HAQ-DI (34% & 44%), entheseal points (75% & 80%). Times to achieve minimal SJC, PASI, and enthesitis with GUS were significantly faster than for PtGA, Pt Pain, TJC, and HAQ-DI for native-scale scores; when normalized, PtGA, Pt Pain, and HAQ-DI were achieved less often (Figure 1). Higher baseline (BL) Pt Pain score and lower BL Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score (worse fatigue) were significant predictors of longer time; lower BMI was associated with shorter time to achieve Pt Pain ≤15. Results for achieving Pt Pain ≤15 at W100 were similar. Worse baseline fatigue and PtGA were significant predictors of longer time to PtGA ≤20; worse fatigue also predicted non-achievement of PtGA ≤20 at W100. For time to achieve HAQ-DI ≤0.5, significant BL negative predictors were higher age and BL HAQ-DI score, which were also significant predictors of HAQ-DI ≤0.5 non-achievement at W100. Although seen in only a small number of pts, a significant impact of FM history and suicidal ideation/behavior on Pt Pain ≤15 and HAQ-DI ≤0.5, respectively, was observed (Table 1).Table 1.Predictors of Time to Achievement and Achievement of Recalcitrant MDA Domains at Week 100 in GUS-randomized Pts (N=492)Time to achievementIndependent BL VariablesPt Pain ≤15PtGA ≤20HAQ-DI ≤0.5HR (95% CI)HR (95% CI)HR (95% CI)Age-0.98 (0.97-0.99)†HAQ-DI-0.26 (0.19-0.36)‡PtGA VAS-0.99 (0.98-1.00)*-Pain VAS0.99 (0.98-1.00)†-FACIT-Fatigue§1.02 (1.00-1.03)*1.02 (1.01-1.04)‡-BMI0.98 (0.96-1.00)*FM (N=8)0.70 (0.55-0.90)†--Achievement at W100OR (95% CL)∥OR (95% CL)∥OR (95% CL)∥Age--0.98 (0.96: 1.00)*HAQ-DI--0.13 (0.08: 0.20)‡Pain VAS0.98 (0.97: 1.00)†--FACIT-Fatigue§1.02 (1.00: 1.05)*1.05 (1.03: 1.07)‡-BMI0.97 (0.94: 1.00)*--Suicidal Ideation/Behaviour (N=9)--0.16 (0.03: 0.86)*FM (N=8)0.59 (0.40: 0.86)†--HR Hazard Ratio CI Confidence Interval OR Odds Ratio CL Confidence Limits*p <0.05; †p <0.01; ‡p ≤0.0001§Higher score indicates less fatigue∥Wald CLConclusionGUS provided continuous improvement in each MDA domain through W100. BL domain score, as well as age, fatigue, and BMI, were significant determinants of MDA achievement in recalcitrant pt-driven domains (Pt Pain, PtGA, HAQ-DI). The impact of FM and mental health status merits further evaluation.References[1]Rahman et al. BMJ Open 2017;7(8): e016619Disclosure of InterestsLaura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Proton Rahman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: Janssen and Novartis, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Inmagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC,, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Iain McInnes Shareholder of: Causeway Therapeutics, and Evelo Compugen, Consultant of: Astra Zeneca, AbbVie, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB, Grant/research support from: Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, GSK, Janssen, Novartis, Roche, and UCB, Lai-Shan Tam Consultant of: Janssen, Pfizer, Sanofi, AbbVie, Boehringer Ingelheim, and Lilly, Grant/research support from: Amgen, Boehringer Ingelheim, Janssen, GSK, Novartis and Pfizer
46
Curtis, J., A. Deodhar, E. Soriano, E. Rampakakis, M. Shawi, N. Shiff, M. Strauss, C. Han, W. Tillett, and D. D. Gladman. "AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1762–63. http://dx.doi.org/10.1136/annrheumdis-2023-eular.515.
Full textAbstract:
BackgroundThe Group for Research and Assessment of Psoriasis and PsA advocates addressing all aspects of disease, including optimizing functional status and improving health-related quality of life (HRQoL).[1]Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at week (W) 24, with effects sustained or further enhanced through 2 years.[2-4]Timing of clinically meaningful improvement in disease activity (DA), functional status, and HRQoL is of interest to PsA patients (pts) and providers.Objectives1) Evaluate effect of GUS on time to minimally clinically important improvements (MCII) in pt reported outcomes and composite measures of DA; 2) Assess association between W4/W8 MCII achievement and later disease control (W24/W52).MethodsThis post hoc analysis evaluated 1120 adults with active PsA despite standard therapies from DISCOVER-1 (D1) (swollen & tender joint counts [SJC/TJC] ≥3 each, CRP ≥0.3 mg/dL, 1-2 prior TNF inhibitors [TNFi] in 31% of pts) and D2 (SJC/TJC ≥5 each, CRP ≥0.6 mg/dL, biologic-naïve). Pts were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then Q8W; or placebo (PBO)→GUS 100 mg Q4W at W24. Time to MCII in outcomes of interest, i.e., improvement in cDAPSA ≥5.7, Joint Visual Analogue Scale [VAS] ≥15mm, Pt Pain ≥15mm, HAQ-DI ≥0.35, PASDAS ≥0.8, PtGA ≥15mm, Skin VAS ≥15mm, FACIT-F ≥4, SF-36 PCS ≥5, was compared between GUS vs PBO with Cox regression adjusting for baseline (BL) levels of respective outcome, treatment group, prior TNFi use, and BL DMARD use. MCII achievement was determined using non-responder imputation and compared between GUS and PBO using logistic regression adjusting for the above covariates. The association between MCII achievement at W4/W8 and stringent clinical response at W24/W52 amongst GUS-treated pts was assessed with logistic regression adjusting for prior TNFi use and BL DMARD use.ResultsTime to achieve MCII in all studied outcomes was significantly shorter (hazard ratio range: 1.3-2.5; all p<0.01) for both GUS Q4W and Q8W vs PBO, including cDAPSA as a representative example (Figure 1), with curve separation occurring at the first timepoint assessed. MCII rates also were significantly higher with GUS vs PBO at the first timepoint assessed, i.e., W4 for cDAPSA, Joint VAS, Pt Pain, and HAQ-DI and W8 for PASDAS, PtGA, Skin VAS, FACIT-F, and SF-36 PCS (Table 1).W4 achievement of MCII in cDAPSA, Joint VAS, Pt Pain, and HAQ-DI was associated with greater odds of achieving future disease control, defined as ACR50, ACR70, cDAPSA ≤13, PASDAS ≤3.2, and MDA, at W24 (odds ratio [OR] range: 1.5-3.6) and W52 (OR: 1.2-2.4). W8 achievement of MCII in all studied outcomes was also associated with greater odds of achieving disease control at W24 (OR: 1.4-17.2) and W52 (OR: 1.2-5.4).ConclusionIn pts with active PsA, treatment with GUS was associated with more rapid MCII in both clinical and pt reported outcomes compared with PBO. As early as W4, achievement of MCII vs non-achievement in each studied outcome, particularly PASDAS and cDAPSA, was associated with greater odds of longer-term stringent DA control. Findings highlight the impact of these rapid improvements with GUS - as early as W4 - on the trajectory of long-term pt outcomes.References[1]Coates LC, et al.Nat Rev Rheumatol2022;18:465[2]Deodhar A, et al.Lancet2020;395:1115[3]Mease PJ, et al.Lancet2020;395:1126[4]McInnes IB, et al.Arthritis Rheumatol2022;74:475Table 1.Proportions of Pts Achieving MCIIEndpoint with MCIIWeekGUS Q4WGUS Q8WPBOcDAPSA4¥58.5%†57.9%†46.8%873.9%‡72.1%‡56.8%Joint VAS4¥31.9%†34.1%‡21.1%845.3%‡45.7%‡30.7%Pt Pain4¥27.8%†29.4%†18.9%844.7%‡44.1%‡28.1%HAQ-DI4¥33.9%†30.5%*22.7%841.7%‡42.6%‡27.6%PASDAS8¥68.4%‡64.9%‡44.0%PtGA8¥53.4%‡53.7%‡32.9%Skin VAS8¥64.0%‡62.1%‡35.2%FACIT-F8¥51.1%*53.1%†43.4%SF-36 PCS8¥43.2%†41.6%35.8%*nominal p <0.05;†p <0.01;‡p ≤0.0001 vs PBO.¥First time point assessed.Acknowledgements:NIL.Disclosure of InterestsJeffrey Curtis Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly and Company, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly and Company, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB, Atul Deodhar Speakers bureau: Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, May Shawi Shareholder of: Johnson & Johnson, Employee of: Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Natalie Shiff Shareholder of: AbbVie, Gilead, Iovance, Jazz Pharmaceuticals, Johnson & Johnson, Novavax, and Viatris, Employee of: Janssen Scientific Affairs, LLC, a subsidiary of Johnson & Johnson, Marcie Strauss Consultant of: Janssen Scientific Affairs, LLC, Employee of: MEDASOURCE, Chenglong Han Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC of Johnson & Johnson, William Tillett Speakers bureau: Abbvie, Amgen, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Consultant of: Abbvie, Amgen, Eli-Lilly, Janssen, MSD, Novartis, Ono-Pharma, Pfizer, and UCB, Grant/research support from: Abbvie, Amgen, Eli-Lilly, Janssen, Pfizer and UCB, Dafna D Gladman Consultant of: Abbvie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, Eli Lilly, Janssen, Pfizer, UCB.
47
V. H. Solonenko, Zh. S. Musaiev, and A. N. Nemasinova. "The working experience in projection to uptake rolling stock “ TALGO” on Kazakstan railways." Science and Transport Progress, no. 38 (September 25, 2011): 32–34. http://dx.doi.org/10.15802/stp2011/6803.
Full textAbstract:
The analysis of technical features and constructive advantages of cars manufactured by Spanish company «Talgo» is carried out. The analysis of operation of the high-speed rolling stock «Talgo» is carried out and the possibility of using new passenger coaches «Talgo» for high-speed traffic is considered.
48
More, K. L., and R. A. Lowden. "Characterization of interfaces in CVD-coated nicalon fiber-reinforced SiC." Proceedings, annual meeting, Electron Microscopy Society of America 47 (August 6, 1989): 556–57. http://dx.doi.org/10.1017/s0424820100154755.
Full textAbstract:
The mechanical properties of fiber-reinforced composites are directly related to the nature of the fiber-matrix bond. Fracture toughness is improved when debonding, crack deflection, and fiber pull-out occur which in turn depend on a weak interfacial bond. The interfacial characteristics of fiber-reinforced ceramics can be altered by applying thin coatings to the fibers prior to composite fabrication. In a previous study, Lowden and co-workers coated Nicalon fibers (Nippon Carbon Company) with silicon and carbon prior to chemical vapor infiltration with SiC and determined the influence of interfacial frictional stress on fracture phenomena. They found that the silicon-coated Nicalon fiber-reinforced SiC had low flexure strengths and brittle fracture whereas the composites containing carbon coated fibers exhibited improved strength and fracture toughness. In this study, coatings of boron or BN were applied to Nicalon fibers via chemical vapor deposition (CVD) and the fibers were subsequently incorporated in a SiC matrix. The fiber-matrix interfaces were characterized using transmission and scanning electron microscopy (TEM and SEM). Mechanical properties were determined and compared to those obtained for uncoated Nicalon fiber-reinforced SiC.
49
Marbun, Jaminuddin. "Peranan Hubungan Industrial." JUPIIS: JURNAL PENDIDIKAN ILMU-ILMU SOSIAL 12, no. 1 (April 30, 2020): 254. http://dx.doi.org/10.24114/jupiis.v12i1.17582.
Full textAbstract:
In general, the rich man becomes an entrepreneur and owns a company while those who run the company are workers and in general the entrepreneur sets up his company for profit. The advantage can be achieved in the company if high productivity and cost savings are incurred by the entrepreneur. Usually one of the ways of savings done by employers is not raising workers 'wages or adding workers' facilities such as not providing work clothes, not providing transportation money and others. The policy of the employer in his company that does not increase the wages of workers and facilities, even though productivity is demanded so that high will harm workers. Workers are generally in a weak position and this is due to more job seekers than available job openings. If vacancies are balanced with job seekers, the bargaining position between employers and workers has the same position. Weak workers in working relationships with employers requires government intervention as coaches, supervisors and protectors for workers and employers. The existence of interference from the government in employment relations for the production process of goods and or services is already an industrial relationship.
50
Hashimoto, T., S. Pyon, Y. Iijima, S. Sugiura, S. Uji, T. Terashima, and T. Tamegai. "Fabrication of a Compact High-field Magnet by Coated Conductor Stacks." Journal of Physics: Conference Series 1293 (September 2019): 012038. http://dx.doi.org/10.1088/1742-6596/1293/1/012038.
Full text